Characterization of new chemosensitizing agents by Schyschka, Lilianna
  
 
Dissertation zur Erlangung des Doktorgrades 
der Fakultät für Chemie und Pharmazie 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
Characterization of new chemosensitizing agents: 
spongistatin 1 and T8 
 
 
 
 
Lilianna Schyschka 
aus Pyskowice 
 
 
2009
  
 
 
 
Erklärung 
Diese Dissertation wurde im Sinne von § 13 Abs. 3 bzw. 4 der Promotionsordnung vom 29. 
Januar 1998 von Frau Prof. Dr. A. M. Vollmar betreut. 
 
 
 
Ehrenwörtliche Versicherung 
Diese Dissertation wurde selbständig, ohne unerlaubte Hilfe erarbeitet. 
 
München, am 19.01.2009 
 
Lilianna Schyschka 
 
 
 
 
 
 
 
 
Dissertation eingereicht am:  19.01.2009 
1. Gutachter:  Frau Prof. Dr. A. M. Vollmar 
2. Gutachter:  Herr Prof. Dr. F. Böckler 
Mündliche Prüfung am: 13.02.2009 
 
Contents 
I 
 
 
Table of contents 
I Introduction ....................................................................................................... 1 
1 Background ......................................................................................................... 1 
2 Aim of the study .................................................................................................. 2 
3 Spongistatin 1 ...................................................................................................... 3 
4 Pharmacophore-based virtual screening for the discovery of target-specific 
compounds .......................................................................................................... 5 
5 Classification of cell death .................................................................................. 6 
6 Apoptosis ............................................................................................................ 7 
6.2 Caspases .............................................................................................................. 7 
6.2.1  Caspase structure and classification .................................................................... 8 
6.2.2  Caspase activation ............................................................................................... 9 
6.2.3  Caspase substrates ............................................................................................. 10 
7 Extrinsic apoptotic pathway .............................................................................. 10 
8 Intrinsic apoptotic pathway ............................................................................... 12 
9 Bcl-2 protein family .......................................................................................... 14 
10 IAP family ......................................................................................................... 14 
10.2 X-linked Inhibitor of Apoptosis Protein ........................................................... 16 
10.2.1  Bir1 domain of XIAP ........................................................................................ 17 
10.2.2  Bir2 and Bir3 domains of XIAP ....................................................................... 18 
10.2.3  RING domain of XIAP ..................................................................................... 18 
II Materials and Methods ................................................................................... 19 
1 Materials ............................................................................................................ 19 
1.1 Compounds ....................................................................................................... 19 
1.2 Reagents ............................................................................................................ 19 
1.3 Equipment ......................................................................................................... 20 
2 Pharmacophore-based virtual screening for XIAP inhibitors ........................... 20 
3 Cell culture ........................................................................................................ 21 
3.2 Cell lines ........................................................................................................... 21 
3.3 Primary cell isolation ........................................................................................ 22 
3.4 Cell culture ........................................................................................................ 22 
3.5 Splitting and seeding for experiments ............................................................... 23 
3.6 Freezing and thawing ........................................................................................ 24 
4 Cytotoxicity measurement (MTT assay) ........................................................... 25 
5 Proliferation measurement ................................................................................ 25 
6 Light and fluorescence microscopy .................................................................. 25 
7 Flow cytometry ................................................................................................. 26 
7.1 Nicoletti assay ................................................................................................... 27 
8 Western blot ...................................................................................................... 28 
Contents 
II 
 
8.2 Preparation of samples ...................................................................................... 29 
8.2.1 Whole lysate preparation .................................................................................. 29 
8.3 Preparation of cytosolic and mitochondrial fractions ....................................... 29 
8.4 Protein quantification ........................................................................................ 30 
8.5 SDS-PAGE ........................................................................................................ 31 
8.6 Western blotting and detection ......................................................................... 32 
8.7 Membrane stripping .......................................................................................... 34 
8.8 Staining of gels and membranes ....................................................................... 34 
9 Caspase activity assay ....................................................................................... 34 
10 Clonogenic survival assay ................................................................................. 35 
11 Reporter gene assay .......................................................................................... 35 
12 TaqMan reverse-transcriptase-polymerase chain reaction ................................ 37 
13 Transformation of bacteria and plasmid purification ........................................ 37 
14 Fluorescence polarization assay ........................................................................ 38 
15 Nuclear magnetic resonance analysis ................................................................ 39 
16 Statistics ............................................................................................................ 39 
III Results .............................................................................................................. 41 
1 Spongistatin 1 .................................................................................................... 41 
1.1 Spongistatin 1 induces cell death in Jurkat leukemia T cells ............................ 41 
1.2 Spongistatin 1 induces cell death in primary leukemic cells ............................ 42 
1.3 Spongistatin 1 inhibits clonogenic survival of Jurkat leukemic T cells ............ 44 
1.4 Spongistatin 1 induce caspase-dependent apoptosis ......................................... 45 
1.5 The extrinsic apoptotic pathway is not important for spongistatin 1 to induce 
apoptosis ............................................................................................................ 47 
1.6 Caspase-9 is essential for spongistatin 1 mediated apoptosis ........................... 48 
1.7 Mitochondria play a pivotal role in spongistatin 1 induced cell death ............. 49 
1.8 Bcl-2 and Bcl-xl overexpression saves Jurkat cells from spongistatin 1 induces 
cell death ........................................................................................................... 50 
1.9 Spongistatin 1 induces cell death in XIAP overexpressing Jurkat cells ........... 51 
1.10 Spongistatin 1 reduces XIAP protein level ....................................................... 52 
1.11 Spongistatin 1 sensitizes Jurkat cells for staurosporine treatment .................... 53 
2 Search for XIAP inhibitors ............................................................................... 55 
2.1 Virtual search for XIAP inhibitors – the pharmacophore model ...................... 55 
2.2 Cellular models for the in vitro validation of virtual screening hits ................. 56 
2.3 The synthetic compound T8 as XIAP inhibitor ................................................ 57 
2.3.1 T8 sensitizes different Jurkat cell lines for etoposide treatment ....................... 59 
2.3.2 T8 in combination with etoposide inhibits clonogenic growth of Jurkat cells . 59 
2.3.3 T8 derivatives .................................................................................................... 60 
2.3.4 T8 sensitizes different cancer cells for doxorubicin treatment ......................... 64 
2.3.5 T8 sensitizes PancTu1 cells for TRAIL treatment ............................................ 64 
Contents 
III 
 
2.3.6 T8 in combination with etoposide decreases clonogenic survival of pancreas 
cancer cells ........................................................................................................ 65 
2.3.7 T8 in combination with cytotoxic drugs is not toxic for HUVECs .................. 66 
2.3.8 T8 reduces XIAP protein level .......................................................................... 67 
2.3.9 T8 enhances etoposide induced caspase-dependent apoptosis .......................... 68 
2.3.10 T8 in combination with etoposide increase caspase activity ............................ 69 
2.3.11 T8 in combination with etoposide activates the intrinsic caspase cascade ....... 70 
2.3.12 Fluorescence polarization assay ........................................................................ 71 
2.3.13 NMR analysis .................................................................................................... 72 
2.3.14 T8 inhibits NF-κB activation ............................................................................ 75 
IV Discussion ................................................................................................................. 76 
1 Spongistatin 1 .................................................................................................... 76 
1.1 Spongistatin 1 is a potent new anticancer agent ............................................... 76 
1.2 Spongistatin 1 induces caspase dependent cell death in leukemic cells ........... 76 
1.3 Spongistatin 1 overcomes XIAP resistance ...................................................... 77 
1.4 Spongistatin 1 sensitizes leukemic cells for staurosporine treatment ............... 77 
1.5 Concluding remarks and future directions ........................................................ 78 
2 T8 as a XIAP inhibitor ...................................................................................... 79 
2.1 T8 in combination with etoposide significantly increases cell death in leukemia 
cells ................................................................................................................... 79 
2.2 T8 analogues ..................................................................................................... 80 
2.3 T8 sensitizes different cancer cells for cytotoxic drugs .................................... 80 
2.4 T8 is not toxic for the healthy cells ................................................................... 81 
2.5 T8 reduces XIAP protein level and contributes to caspase dependent apoptosis 
 ........................................................................................................................... 81 
2.6 T8 does not bind to Bir3 or Bir2 domain of XIAP ........................................... 82 
2.7 T8 reduces NF-κB activation ............................................................................ 82 
2.8 Concluding remarks and future directions ........................................................ 83 
V Summary .......................................................................................................... 84 
VI References ........................................................................................................ 86 
VII Appendix .......................................................................................................... 93 
1 Abbreviations .................................................................................................... 93 
2 Alphabetical list of companies .......................................................................... 97 
3 Publications ....................................................................................................... 99 
4 Curriculum vitae ............................................................................................. 101 
5 Acknowledgments ........................................................................................... 102
I Introduction 
1 
 
I Introduction 
1 Background  
Cancer, together with cardiovascular and infectious diseases, belongs to the three leading 
causes of death in the world [1]. Thus, anti-cancer strategies are of high scientific interest. 
The idea of treating cancer with drugs is about 500 years old, when first mixtures of zinc, 
silver and mercury were used. Certainly, the first documented treatment of cancer with 
chemotherapeutics refers to the German doctor Lissauer, who had treated leukemia patients in 
1865 with potassium arsenite [2]. Although better understanding of cancer pathophysiology 
and the development of new agents caused therapeutic progress in cancer treatment, resistence 
to established agents has been described. Thus, new drugs and the development of more 
effective strategies to treat cancer and to overcome chemoresistance are still urgently 
required. 
Natural products play a pivotal role as a source of new drugs. After analyzing the available 
anticancer drugs of the last 25 years it is obvious that the majority of the new approved drugs 
are natural or natural-related compounds (see Figure I.1) [3]. Such natural products as the 
vinca alkaloids vinblastine and vincristine, isolated from the Madagascar periwinkle 
(Catharanthus roseus), or paclitaxel originally isolated from the bark of the pacific yew tree, 
Taxus brevifolia, significantly contribute to the successful treatment of many cancers. 
The screening program of the U. S. National Cancer Institute (NCI) identified many 
compounds from natural sources that show anti-cancer activity. Currently, the screen consists 
of 60 different tumor cell lines which are treated with compounds to assess selective growth 
inhibition or cell killing. This screen is unique in its complexity since the effectiveness of a 
compound on a large number of different cancer types (e.g. leukemia, breast cancer, lung 
cancer, melanoma, ovary cancer) can be tested which leads to characteristic profile 
generation. NCI-founded groups collected e.g. marine organisms, mostly invertebrates, 
isolated new compounds out of them and subsequently tested the substances in the in vitro 
screening program [4]. This search led to the discovery of such active compounds as 
dolastatin, halichondrine B or bryostatin 1, which are now evaluated in clinical trials. 
The large number of natural products and the huge amount of information about their 
structural and biological activities makes it difficult to handle with this data. On the other 
hand the progress in understanding the fundamental principles of protein-ligand interactions 
and targets in the anti-cancer therapy provides new possibilities for rationalized drug 
discovery. The computational approaches, like virtual screening experiments, have already 
successfully been applied to find new target-specific drugs [5, 6]. The common idea of these 
approaches, the in silico selection of a limited number of potential agents which are proposed 
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to have biological activity, results in time- and cost- reduction in the discovery of new drug. 
Thus, applying computational approaches within the early drug discovery process can have 
great benefits for the search of new active anti-cancer drugs. 
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Figure I.1 Classification of all available anticancer drugs (from 1940 to 2006) by source (from [3]) 
The analyses of all available anticancer drugs show that natural products play a dominant role in the discovery of 
leads for the development of drugs for cancer treatment. The chart shows the sources of anticancer drugs: natural 
products (N); biological, usually large peptides or proteins (B); derived from a natural product, usually with 
semisynthetic modifications (ND); total synthetic drugs (S); made by total synthesis, but the pharmacophore was 
from a natural product (S*); vaccine (V); natural product mimic (NM). 
2 Aim of the study 
Chemoresistance is a major difficulty in successful cancer treatment. It is related to 
deregulation and alterations in proteins involved in apoptosis, a form of programmed cell 
death. In many types of cancer, proapoptotic proteins have inactivating mutations as well as 
antiapoptotic proteins are often upregulated [7, 8], resulting in ineffective therapy outcome. 
Thus, new effective compounds that target multiple signaling pathways and restore the 
programmed cell death in cancer cells are still urgently required. 
Therefore, the aim of this work was:  
1 the characterization of apoptotic potential of spongistatin 1 in chemoresistant leukemia 
cells 
2 the identification and pharmacological evaluation of new compounds selected from 
pharmacophore-based virtual screening on its ability to inhibit anti-apoptotic XIAP-
Bir3 protein and restore programmed cell death in cancer cells. 
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3 Spongistatin 1 
Spongistatin 1 (Figure I.2) was isolated from the Eastern Indian Ocean (Republic of 
Maladives) sponge Hyrtios erecta. The group of G. R. Pettit (Arizona State University, USA) 
found this marine Porifera during its expedition in 1988 [9]. Only 5 mg of this macrocyclic 
lactone were isolated from the 400 kg of wet sponge. 
In the same time the group of Kobayashi found an identical structure in the Okinawan marine 
sponge Hyrtios altum (Figure I.2C) [10] and named it Altohyrtin A. 
A B
C
 
Figure I.2 Chemical structure of spongistatin 1 (A), Hyrtios erecta (B) and Hyrtios altum (C) 
Spongistatin 1 belongs to the macrocyclic lactones (A) and was isolated from (B) Hyrtios erecta [11] and (C) 
Hyrtios altum [12]. 
 
Spongistatin 1 was tested in the NCI panel of 60 human cancer cell lines (see Figure I.3) and 
identified to be extraordinary potent against twenty of them. The analysis of the data from 
NCI screen using the computerized, pattern-recognition algorithm COMPARE shows profile 
similarities between spongistatin 1 and such antimitotic agents as vincristine, vinblastine, 
taxol or podophyllotoxin [13]. Indeed, this correlation could be validated by experiments of 
Bai et al. [14], that show that spongistatin 1 binds to the same pocket of tubulin as vinblastine 
and GTP. Thereby, spongistatin 1 hinders interactions of tubulin interdimers and contributes 
to depolimerization of tubulin. Spongistatin 1, for the first time introduced as a broad 
spectrum antifungal compound [15], was also tested in a pancreas KCI-MOH1 cell line-
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derived SCID mouse xenograft model and showed synergistic antitumor effects in 
combination with gemcitabine [16]. 
 
Figure I.3 The cytotoxic profile of spongistatin 1 evaluated by the NCI in vitro assay [13] 
The zero value represents the mean of all cell lines tested. The bars indicate the deviation of the mean data 
obtained from the individual cell line from the overall mean and mark the sensitivity of the cell lines for 
spongistatin 1 (the negative bars represent more sensitive cell lines than the calculated average; the positive bars 
represent the less sensitive ones). GI50: 50 % growth inhibition after the 48 hrs cytotoxicity assay. 
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4 Pharmacophore-based virtual screening for the 
discovery of target-specific compounds 
The continuously increasing amount of relevant molecular targets in cancer therapy and the 
progress in understanding of the molecular processes within cells allow searching for target-
specific compounds. These are characterized by selectivity for cancer cells and therefore show 
fewer side effects on healthy cells. In this searching process various in silico tools can provide 
help to rational discovery of bioactive anti-cancer compounds. 
A pharmacophore is the ensemble of steric and electronic features that is necessary to ensure 
the optimal supramolecular interactions with a specific biological target structure and to 
trigger (or to block) its biological response [17]. Thus, pharmacophore models are useful tools 
for drug discovery. There exist two approaches for developing pharmacophore models: either 
by analyzing the known structure of the target molecule (structure-based design) or by 
starting from a set of ligands which are supposed to bind to the same area within the target 
(ligand-based design). For structure-based model generation (Figure I.4) the information 
about 3D structure of a ligand conformation, combined with the exact binding site of the 
target to ligand is needed [18]. This information can be obtained from the Brookhaven Protein 
Data Bank (PDB) [19], an unique platform containing 3D coordinates of ligand and target 
structures from NMR and co-crystal experiments. The use of software tools such as 
LigandScout [20] automates the modeling process. It incorporates the data from 3D 
interaction structure including such chemical features as hydrogen bond donors, acceptors, 
lipophilic areas or positively and negatively ionizable chemical groups into the structure-
based pharmacophore model [20]. This tool is ideally used for virtual screening of large 
databases and to make predictions about the biological activity of chemical compounds. 
The application of pharmacophore models in virtual screening of large databases allows the 
selection of a limited number of agent-candidates proposed to have biological activity. 
Moreover, the molecules that do not possess the essential features of ligand-target interaction 
quickly get eliminated and fewer in vitro experiments have to be performed [21]. Hence, the 
structure-based pharmacophore model used as a filter can hugely enrich the hit rate of 
bioactive compounds in comparison to random screening. 
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Figure I.4 Identification of new bioactive compounds by pharmacophore-based virtual screening 
The information from 3D structures of proteins and their targets is used as a starting point for structure-based 
pharmacophore model generation. As the next step, virtual screening of large compound databases can be 
prepared and the hits can be validated via its biological activity in pharmacological tests. 
5 Classification of cell death 
The rapid development of new techniques in molecular biology makes it difficult to clearly 
classify the different cell death modalities. Based on the Nomenclature Committee on Cell 
Death (NCCD) proposal a cell is regarded as dead if any of the following molecular or 
morphological events can be detected: (i) the cell membrane is not intact any longer, (ii) the 
cell is fragmented into “apoptotic bodies” and (iii) its fragments have been engulfed by a 
neighboring cell (in vivo) [22]. 
There are two distinct ways by which cells can die. The first one is the so called programmed 
cell death (PCD), which is characterized by the activation of genetically encoded biochemical 
processes and by saving the tissue from inflammation (Figure I.5). The PCD classification 
includes different cell death forms such as apoptosis and autophagy. 
The second way by which cells can die is necrosis, it ends in the uncontrolled destruction of 
the cell body and causes tissue inflammation. A characteristic sign of necrosis is the increased 
cell volume (oncosis) and the swelling of organelles, finally leading to plasma membrane 
rupture and inflammation of neighbor tissue. Initially, necrosis was defined as a completely 
accidental process of cell death but recent research has figured out that it can be a regulated 
process as well, mediated through a set of cellular pathways involving death domain- and 
Toll-like- receptors. 
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Figure I.5 Overview of necrosis and apoptosis  
Necrosis is characterized through cell swelling and membrane rapture. The cellular content is released into the 
surrounding tissue, resulting in inflammation. In apoptosis the cell volume decreases, the chromatin is condensed 
and fragmented; cell organelles are enclosed in apoptotic bodies which are later phagocyted through 
macrophages. 
6 Apoptosis 
Apoptosis is an important cell death program that occurs both, in the developing and in the 
adult organism. The balance between proliferation and cell death is necessary for tissue 
homeostasis. Thus, an increase, a decrease or defects in the apoptotic process cause many 
pathological disorders such as autoimmune diseases, neurodegenerative diseases or cancer 
[23]. Apoptosis can be trigged by a variety of extrinsic and intrinsic pathway-induced signals. 
In both cases caspases are the essential players in the cell death process. 
6.2 Caspases 
Caspases are an evolutionary conserved family of cysteinyl-aspartate specific proteases which 
are involved in the cleavage of key protein substrates finally leading to apoptosis. Caspase-1 
was identified in 1992 [24, 25] as the interleukin-1β-converting enzyme (ICE) which cleaves 
the precursor interleukin-1β after Asp116, thereby producing the active cytokine. At that time 
nothing was known about a role of ICE in apoptosis. Not before 1993, the group of Horvitz 
cloned the C. elegans gene ced-3 and showed the similarity to human ICE and the mouse 
nedd-2 gene [26]. They also proposed that the CED-3 protein acts as a cysteine protease in the 
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initiation of PCD in C. elegans and those cysteine proteases may have the same role in 
mammals. At least 14 caspases are identified up to now. 
6.2.1 Caspase structure and classification 
Caspases involved in apoptosis are divided into two groups: the initiator caspases (caspase-2, 
-8, -9, and -10) and effector caspases (caspase-3, -6, and -7).  
All caspases are produced as inactive zymogens, which are activated either by autocleavage 
(initiator caspases) or cleavage by other caspases (effector caspases). The cleavage occurs at a 
specific internal aspartic acid residue (see Figure I.6) and produces two subunits: a large (20 
kDa) and a small one (10 kDa). 
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Figure I.6 Schematic diagram of the different caspase structures (adopted from [27]) 
Structure of human caspases (except caspase-11, -12 [mouse] and -13 [bovine]). The initiator and effector 
caspases are labeled in red and green, respectively. The bold arrows show the first activation cleavage, small 
arrows indicate additional sites of cleavage. The L1-L4 indicates the four surface loops that shape the catalytic 
groove. The red line at the beginning of L2 loop shows catalytic Cys.  
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6.2.2 Caspase activation 
Caspases (see chapter 6.2.1) play an important role in mammalian apoptosis. The activating 
cleavage takes place within a short peptide fragment which connects the large and small 
subunit of the zymogen and usually occurs at the highly conserved Asp-297 (caspase-1 
numbering convention) (see Figure I.6). In this way, the most activated caspase can process 
itself and other caspase zymogens (see Figure I.7) [28]. 
Initiator caspases are characterized by one or more N-terminal adapter motifs (CARD= 
caspase recruitment domain or DED= death effector domain). These adapter motifs interact 
with similar motifs of the adapter proteins within activation platforms (apoptosome, 
PIDDosome and death inducing signaling complex- DISC). Two theories concerning the 
activation of the initiator caspases are discussed: the induced proximity model and the 
proximity-driven dimerization model [28, 29]. Generally, the initiator caspases get 
autoactivated when caspases are brought very close to each other (e.g. as by the DISC 
complex). For caspase-9 activation the induced conformation model was proposed. The 
apoptosome directly activates monomeric caspase-9 by modification of its active site 
conformation in an unknown process [30, 31]. All models are not mutually exclusive; there 
are several possibilities leading to initiator caspase activation. Once activated, initiator 
caspases can initiate the caspase cascade by proteolytic processing of effector caspases.  
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97
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Figure I.7 Caspase activation by proteolysis (modified from [28]) 
Caspases are synthesized as single chain zymogens. Activation usually occurs by cleavage at the conserved 
D297 (caspase-1 numbering convention). The active caspase is a tetramer of two heterodimers, each comprising 
a large and a small subunit and an active site (grey circle). 
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6.2.3 Caspase substrates 
As mentioned above, the apoptotic process is executed by the caspase-mediated cleavage of 
numerous cellular proteins. As the consequence of this cleavage the caspase substrates are 
activated or inactivated. As the name cysteine-dependent aspartate specific protease implies, 
caspases use their conserved Cys side chain as a nucleophile to hydrolyze peptide bonds and 
they have a primary specificity for Asp. The catalytic cleft of a caspase is responsible for its 
specifity and is formed by the strictly conserved residues Arg179, Arg314 and Gln283 
(caspase-1 numbering convention) and is almost identical for all caspases [32, 33]. Caspases 
recognize 4 specific amino acids residues of their substrates (P1-P4) and have a cleavage 
preference to the position prior first Asp (see Table 1). This feature makes the protelolytic 
cleavage more specific. 
Table 1 Cleavage sites of caspases substrates (from [32]) 
Caspase P5 P4 P3 P2 P1 P1’ 
1, 4, 5, 14  W/Y E X D Φ 
8, 9, 10  I/L E X D Φ 
3, 7  D E X D Φ 
6  V E X D Φ 
2 V/L D E X D Φ 
Φ means that G, A, T, S or N is preferred in position P1’; D the cleavage position 
 
The cleavage by a caspase can activate the substrate, e.g. effector caspases or proapoptotic 
Bid [34]. On the other hand, cleavage can result in a loss of function as in case for the 
poly(ADP-ribose) polymerase (PARP). This enzyme is responsible for the repair of DNA-
strand breaks. After degradation through caspase it loses the ability to restore the DNA 
entireness [35]. 
7 Extrinsic apoptotic pathway 
Apoptosis can be initiated in mammalian cells by two different pathways: (i) by the extrinsic 
way which implicates the activation of death receptors of the tumor necrosis factor (TNF) 
receptor superfamily, or (ii) by the intrinsic way which involves mitochondria and release of 
proapoptotic proteins out of them. There exists a crosslink between these two pathways which 
results in amplification loop. 
The extrinsic pathway is crucial for the proper function of the immune system. Up to date, six 
different death receptors are identified. CD95 (APO1/Fas), TNFRI (tumor necrosis factor 
receptor I) and TRAIL (TNF-related apoptosis-inducing ligand) receptors are the best known. 
They are characterized by the intracellular death domain (DD) which is essential for the 
apoptotic signal transduction [36]. Stimulation of the receptors (e.g. CD95) by binding to their 
ligands (e.g. CD95L) results in the trimerization of the receptors and the recruitment of 
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adaptor molecules like FADD (Fas-associated death domain) which is mediated by its 
interaction with the DD (see Figure I.8). In the following, FADD recruits caspase-8 or -10 
proforms, forming a complex called DISC (death-inducing signaling complex). The 
oligomerization of the caspase zymogens in turn drives their activation by autocleavage (see 
also chapter I.6.2.2). Active caspases then activate effector caspases (e.g. caspase-3) [37]. In 
type I cells, large amounts of caspase-8 are activated leading to the rapid cleavage of caspase-
3. In comparison, in the type II cells the relative amount of activated caspase-8 is insufficient 
for full caspase-3 activation. In this case caspase-8 cleaves Bid protein into truncated Bid (t-
Bid) which in turn induces mitochondria outer membrane permeabilization (MOMP) and the 
activation of effector caspases [34]. 
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Figure I.8 Extrinsic apoptotic pathway 
Binding of the ligand on its receptor leads to receptor trimerization in the membrane and FADD recruitment to 
the complex. Caspase-8 binds to the assembly by its DED domain and the death inducing signaling complex 
(DISC) is formed. On this platform caspase-8 is autoactivated. The initiator caspase-8 activates downstream 
effector caspases (type I cells), or cleaves Bid and leads to an amplification of apoptosis by involving the 
mitochondria (type II cells).  
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8 Intrinsic apoptotic pathway 
Mitochondria represent the central elements of the intrinsic apoptotic pathway. Besides their 
function as energy supplier for the cells, mitochondria contain, between the double-
membrane, important proteins for the initiation of apoptosis. 
Activated by cell death stimuli (e. g. oxidative stress, DNA-damage or signals induced by 
chemotherapeutic drugs) proapoptotic proteins, the cytosolic Bax and mitochondria bound 
Bak form pores in the outer mitochondria membrane (OMM) [38, 39] (see Figure I.9). This 
leads to a decrease of the membrane potential (∆Ψ) and to the release of proapoptotic proteins 
such as cytochrome c, second mitochondria-derived activator of caspase/direct IAP-binding 
protein with low PI (smac/DIABLO), high-temperature requirement protein A2 (Omi/HtrA2), 
apoptosis-inducing factor (AIF) and endonuclease G (endoG) into the cytosol [40]. Once 
released, EndoG and AIF translocate to the nucleus where they are able to induce DNA 
fragmentation in a caspase-independent manner [41, 42]. 
In contrast, in the presence of ATP cytochrome c interacts with Apaf-1 and forms a large 
(about 1.4 kDa) complex- the apoptosome, leading to caspase activation. By its CARD 
domain, caspase-9 is recruited to the CARD domain of Apaf-1 [29, 43]. Caspase-9 gets 
activated and in turn mobilizes activation of caspase-3 and initiates the apoptotic cascade 
which finally causes DNA fragmentation and cell death. 
The proapoptotic proteins smac/DIABLO and Omi/HtrA2 counteract inhibitors of apoptosis 
proteins (IAPs), a conserved family of antiapoptotic proteins responsible for the regulation of 
caspase activity (for detailed description see chapter 10). 
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Figure I.9 Intrinsic apoptotic pathway 
Apoptotic stimuli induce the release of intermembrane proteins from mitochondria into the cytosol. Cytochrome 
c together with Apaf-1, ATP and caspase-9 forms the apoptosome complex that leads to caspase-9 activation and 
results in the activation of effector caspases. The IAPs are able to inhibit both the initiator and effector caspases. 
Smac/DIABLO and Omi/HtrA2 antagonize the IAPs and facilitate caspase activation. After release from 
mitochondria, Omi/HtrA2, AIF and endoG translocate to the nucleus and induce caspase independent cell death. 
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9 Bcl-2 protein family 
In mammals, there exist at least 12 Bcl-2 family proteins which either has pro- or anti- 
apoptotic properties. The Bcl-2 homology (BH) domain is a conserved region among all 
family members and up to date four BH domains could be identified: BH1-BH4. Bcl-2 family 
members have been grouped into three classes [38, 44]. 
First anti-apoptotic class (e. g. Bcl-2 or Bcl-xl) can suppress cell death induction. Most 
proteins belonging to this class possess a hydrophobic tail, which allows the attachment to 
membranes of organelles like mitochondria. They prevent the release of apoptogenic factors 
from mitochondria and therefore protect against outer membrane permeabilization by a not 
fully understood mechanism. 
The second group includes proapoptotic multidomain proteins which share several regions of 
sequence homology (e.g. Bax, Bak or Bok). Bax is loosely attached to the outer membrane of 
mitochondria or is sequestered in cytosol, whereas Bak has an anchor that attaches it to the 
mitochondrial outer membrane. Upon a death stimulus Bak and Bax undergo a 
conformational change, oligomerize and induce the formation of a pore in the OMM leading 
to the release of e.g. cytochrome c and smac/DIABLO. 
The last group, also known as BH3-only proteins, has many members whose common feature 
is the presence of a single BH3 domain. The BH3 domain serves as ligand for Bcl-2 and Bcl-
xl suppression or for Bax and Bak activation. Bid for example is thought to induce the 
conformational change of Bax/Bak, which leads to insertion in the OMM. 
10  IAP family 
The mammalian IAP family consists of eight proteins, that all have at least one Bir domain 
(baculoviral IAP repeat) (see also Figure I.10). The IAPs were discovered in insect cells from 
Spodoptera frugiperda infected with the virus Autographa californica which lacks p35 [45]. 
P35 acts by inhibiting the activity of members of the ICE family of cysteine proteases [46, 
47]. Later the first IAP protein, NAIP was found in mammals [48] and in 1996 the group of 
Thompson showed that IAP can also prevent cell death in mammalian cells [49]. This data 
suggested IAPs to be an evolutionary conserved family involved in apoptosis. It is now 
known that the IAPs are involved in many other cellular functions e.g. protein degradation 
and stabilization, cellular morphogenesis, mitotic chromosome segregation, cell motility or 
copper homeostasis [50-53]. 
The Bir domain of IAP proteins consists of ~70 amino acids with the signature sequence 
CX2CX16HX6C (C= cysteine, H= histidine, and X= any amino acid). The central zinc ion is 
coordinated via histidine and cysteine residues. The Bir domains mediate the protein-protein 
interactions, and although there is high similarity between them they have high specificity for 
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binding partners. It implicates, that the composition of the interaction is completely different 
among the Bir domains. 
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Figure I.10 Schematic structure of the inhibitor of apoptosis protein family (from [54]) 
IAPs have at least one baculoviral IAP repeat (Bir) domain. Additionally, most IAPs have other distinct 
functional domains such as the nucleotide-binding oligomerization domain (NOD), the leucine-rich repeats 
(LRRs) and the really interesting new gene domain (RING), an E3 ligase that presumably directs targets to the 
ubiquitin-proteasome degradation system. Bruce has an ubiquitin-conjugation (UBC) domain that is found in 
many ubiquitin-conjugating enzymes. (cIAP, cellular IAP; IAP, inhibitor of apoptosis protein; ILP, IAP-like 
protein; ML-IAP, melanoma IAP; NAIP, neuronal apoptosis inhibitory protein; XIAP, X-chromosome-linked 
IAP). 
 
Although the IAPs were originally discovered as inhibitors of apoptosis, not all of them 
inhibit caspases with the same efficiency (see Table 2). The most potent caspase inhibitor is 
XIAP (X-linked inhibitor of apoptosis proteins), which prevents both, the activation of the 
initiator caspase-9 as well as of the effector caspases-3 and -7. 
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Table 2 IAP proteins inhibits various caspases with different inhibitory constants (Ki) (adopted from [55-
60]) 
IAP member Inhibited caspase  Ki (nM) 
XIAP  3 
7 
9 
0.7 
0.2 
Not defined 
c-IAP1  3 
7 
108 
42 
c-IAP2  3 
7 
35 
29 
NAIP  3,7 Not defined  
Survivin  3 20.9 
Livin  3,7,9 Not defined 
ILP-2  9 Not defined 
BRUCE  3 Not defined 
10.2 X-linked Inhibitor of Apoptosis Protein 
XIAP (also known as MIHA/hILP/BIRC4) is a key member of the family of intrinsic 
inhibitors of apoptosis proteins (IAP). This 57 kDa protein contains three baculoviral IAP 
repeat (Bir) domains and a C-terminal really interesting new gene domain (RING). XIAP was 
shown to directly bind and inhibit caspases-3, -7 and -9 [61-63]. The structures of XIAP Bir2 
and Bir3 domains have been determined by nuclear magnetic resonance [64, 65] and were 
found to be very similar. However, different sets of amino acids residues were found to be 
responsible for the inhibition of distinct caspases. 
XIAP is involved in many regulatory mechanisms in cells: it is a potent caspase inhibitor [61]. 
It is involved in ubiquitination and proteasomal degradation of many proteins [66] and in the 
activation of NF-κB [66, 67] (Figure I.11).  
The IAP mediated inhibition of caspases is antagonized by a family of proteins that contain an 
IAP-binding motif (IBM). After getting released from mitochondria, smac/DIABLO forms 
homodimers and binds simultaneously to Bir2 and Bir3 domains of XIAP [68] via the IBM 
and restores the caspase activity. Moreover, the mitochondrial protease Omi/HtrA2 binds to 
the Bir domains of XIAP and additionally degrades XIAP [69, 70]. 
The XIAP associated factor 1 (XAF1) negatively regulates XIAP by initiating XIAP 
translocation from cytoplasm into nuclei [71]. Furthermore, calpains mediated XIAP 
degradation [72] and also caspases are able to cleave the XIAP into different fragments [73].  
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Figure I.11 XIAP protein-protein interactions in the cell 
XIAP directly inhibits caspase-3, -7 and -9, promotes proteasomal degradation of smac/DIABLO and caspase-3 
and is able to activate NF-κB pathways. Negative regulators of XIAP are smac/DIABLO, Omi/HtrA2, calpains, 
XAF1 and caspases. XIAP is also able to initiate its self-degradation in autoubiquitination process. 
 
 
XIAP translation is regulated by a unique cap-independent mechanism which allows the 
production of new proteins if the majority of cap-dependent translation initiation is aborted. 
XIAP mRNA contains an internal ribosome entry site (IRES) in its 5’-untranslated region (5’-
UTR) which directly recruits ribosomes to mRNA [74]. 
Interestingly, XIAP deficient mice are viable and show no phenotype. An explanation may be 
the elevated levels of c-IAP1 and c-IAP2 possibly compensating the lack of XIAP [75]. 
10.2.1 Bir1 domain of XIAP 
The Bir1 domain of XIAP, in contrast to Bir2 and Bir3, does not bind the proteins with IBM 
motif, but is indirectly involved in apoptotic events via activation of TAK1 and NF-κB 
pathway [76]. 
The Bir1 and RING domain induce XIAP dimerization (see Figure I.12), stimulating the 
interaction between Bir1 and TGF-β-activated kinase 1-binding protein 1 (TAB1). This 
complex activates TGF-β-activated kinase 1 (TAK1) which in turn activates NF-κB. 
Smac/DIABLO is able to disrupt the Bir1 dimerization and consequently inhibits NF-κB 
activation [67]. After TNFα stimulation, XIAP enhances a second wave of NF-κB nuclear 
translocation by interaction and ubiquitination of MEKK2 [77]. 
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Figure I.12 Bir1 dimerization and NF-κB activation (adopted from [67]) 
The Bir1 and RING domain induce XIAP dimerization and interaction between Bir1 and TGF-β-activated kinase 
1-binding protein 1 (TAB1), the upstream activator of TAK1. Subsequently TAK1 stimulates the NF-κB 
pathway activation. This activation process can be disrupted by smac/DIABLO.  
10.2.2 Bir2 and Bir3 domains of XIAP 
The conserved amino acids within the linker region between the Bir1 and the Bir2 domains 
were found to be critical for inhibition of caspase-3 and -7 [64]. This side linker peptide forms 
together with the Bir2 domain a tight complex with effector caspase and inhibits their 
catalytic activity [62]. 
The Bir3 domain was identified as region of XIAP that specifically inhibits caspase-9 [73]. 
Upon processing of caspase-9 into p12 subunit at Asp315, the four amino-terminal residues 
(Ala-Thr-Pro-Phe) are exposed. These residues interact with XIAP-Bir3 domain and form 
XIAP-caspase-9 heterodimers [78]. The same conserved tetrapeptide sequence of caspase-9 is 
responsible for caspase homodimerization and activation on the apoptosome platform. Thus, 
XIAP sequesters caspase-9 in an inactive monomeric state [63]. 
10.2.3 RING domain of XIAP 
The C-terminal RING (really interesting new gene) domain of XIAP regulates the 
(auto)ubiquitination of target proteins [50, 66]. The RING domain coordinates Zn2+ via three 
cysteine and histidine amino acids. This motif is the basis of the E3 ubiquitin ligase activity of 
XIAP and the platform for binding the E2 ubiquitin-conjugating enzymes. The 
autoubiquitination sites of XIAP are located in the Bir3 domain at Lys322 and Lys328 [66]. 
The RING domain promotes ubiquitination and proteasomal degradation of active caspase-3 
[79] and smac/DIABLO [80] and thus regulates caspase activity at a post-translational level. 
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II Materials and Methods 
1 Materials 
1.1 Compounds 
Spongistatin 1 was kindly provided by G. R. Pettit (Tempe, Arizona, USA) [14]. The T 
substances were purchased from Asinex Ltd. (Moscow, Russland) (see Figure III.20). T8 was 
furthermore synthesized and kindly provided by the group of Prof. K. T. Wanner from 
Department of Pharmacy at the Ludwig Maximilians University in Munich, Germany. The 
ABT-11 compound [81] was kindly provided by Abbott Laboratories (Abbott Park, Illinois, 
USA). 
1.2 Reagents 
CompleteTM  Roche, Mannheim, Germany 
FCSgold PAN Biotech, Aidenbach, Germany 
zVADfmk Calbiochem, Schwalbach, Germany 
Endothelial Growth Medium PromoCell, Heidelberg, Germany 
Hoechst 33342 Sigma, Taufkirchen, Germany 
MTT Sigma, Taufkirchen, Germany 
Propidium iodide Sigma, Taufkirchen, Germany 
Pyruvate Sigma, Taufkirchen, Germany 
Paclitaxel Sigma, Taufkirchen, Germany 
Etoposide  Calbiochem, Schwalbach, Germany 
Doxorubicin HCl  Sigma, Taufkirchen, Germany 
Staurosporine  Cayman Chemical, Ann Arbor, USA 
G418 sulfate PAA Laboratories, Cölbe, Germany 
DMSO AppliChem, Darmstadt, Germany 
Puromycin PAA Laboratories, Cölbe, Germany 
RPMI1640 PAA Laboratories, Cölbe, Germany 
DMEM  PAA Laboratories, Cölbe, Germany 
Ac-DEVD-AFC Bachem, Bubendorf, Germany 
Ac-LEHD-AFC Bachem, Bubendorf, Germany 
TNFα Sigma, Taufkirchen, Germany 
KillerTRAIL Axxora Deutschland GmbH, Lörrach, Germany 
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1.3 Equipment 
ViCELLTM  Beckman Coulter, Krefeld, Germany 
FACS Calibur Beckton Dickinson, Heidelberg, Germany 
Tecan SunriseTM Tecan, Crailsheim, Germany 
Luminometer Berthols Detection Systems, Pforzheim, Germany 
Curix 60 AGFA, Cologne, Germany 
Li-Cor LI-COR Bioscence GmbH, Bad Homburg, Germany 
Thermoshake THO 500 Gerhard, Königswinter, Germany 
2 Pharmacophore-based virtual screening for XIAP 
inhibitors 
The pharmacophore modeling and virtual screening was performed by the group of Prof. 
Hermann Stuppner from the Institute of Pharmacy, Pharmacognosy at the University of 
Innsbruck, Austria. 
A NMR-structure of an antagonist of the XIAP-caspase-9-interaction complex to the BIR3 
domain of XIAP (PDB entry 1TFQ) (Figure II.1) served as primary information for the 
pharmacophore model generation [81]. The data together with the information from structure-
activity relationship (SAR) studies [82, 83] were implemented into the pharmacophore model 
using the Catalyst Software 4.9 (Accelrys Inc., San Diego, USA). To make the 
pharmacophore model more precisely, the side chains of the protein, which could disturb the 
ligand-target interaction, were tagged with exclusion spheres. 
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Figure II.1 Model of an antagonist of the XIAP-caspase-9-interaction complex to the BIR3 domain of 
XIAP (PDB entry 1TFQ) 
 
Before initiation of the large virtual screening, the pharmacophore model (Hypo2-
1TFQexcludvolumes7) was validated in a self made database of 30 compounds which are 
well known to inhibit XIAP-Bir3 interaction.  
To retrieve a limited number of virtual hits, a consensus screening was applied using the 
GRID-based pharmacophore model [43, 84]. The resulting hypothesis was incorporated into 
Hypo2-1TFQexcludvolumes7 model. The virtual screening of commercial available databases 
(Asinex Platinum 1104, Asinex Gold 1104, Specs 110, Maybridge 2004 Derwent WDI_2003 
and NCI) was performed by Catalyst Software. 
Test compounds were selected from the virtual screening hits according to the (i) best fit 
values derived from consensus screening, (ii) compound availability, (iii) fulfilment of the 
Lipinski “rule of five” and (iv) experience based on toxicity prediction. 
3 Cell culture 
3.2 Cell lines 
Human leukemia Jurkat T cells (wild type Jurkat clone J16, S-Jurkat), empty vector (Neo-
Jurkat), Bcl-2 overexpressing Jurkat cells (Bcl-2 Jurkat), Bcl-xl overexpressing Jurkat cells 
(Bcl-xl Jurkat), CD95-deficient Jurkat cells (R-Jurkat) [85] wild type A3-Jurkat cells, FADD 
deficient A3 (FADD-/- Jurkat) and caspase-8 deficient Jurkat cells (8-/-) [86] were obtained 
from H. Walczak and P. H. Krammer (Heidelberg, Germany). Caspase-9 deficient Jurkat cells 
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(9-/-) were kindly provided by K. Schulze-Osthoff, Düsseldorf, Germany. Empty vector 
Jurkat cells (pBabe), XIAP overexpressing Jurkat cells (XIAP-Jurkat), and Bir3/RING 
overexpressing Jurkat cells were kindly provided by C. Duckett (Ann Arbor, Michigan, 
USA). LNCAP cells were provided by I. Jeremias (Munich, Germany) and MDA-MB-231 
cells were a kind gift from B. Bachmeier (Munich, Germany), PancTu1 cells were obtained 
from S. Fulda (Ulm, Germany) [87] and L3.6pl cells were obtained from C. Bruns (Munich-
Großhadern, Germany) [88]. Human embryonic kidney-293 cells (HEK-293) were obtained 
from DSMZ. 
3.3 Primary cell isolation 
Human peripheral mononuclear blood cells (PMBCs) were freshly isolated from the blood of 
healthy human donors. Blood, anticoagulated with EDTA (1mg EDTA/ml blood), was diluted 
with an equal volume of PBS+ and layered without mixing over Ficoll Paque PLUS 
(Amersham Pharmacia Biotech, Uppsala, Sweden) in a 50 ml falcon. After 0.5 hrs of 
centrifugation at 400 x g, the top layer containing plasma was carefully removed and the 
PMBCs were harvested into a new tube. Cells were washed twice with PBS+ to remove rests 
of Ficoll solution and recovered in fresh medium. 
Primary leukemic blasts were obtained from children treated for acute leukemia at the Ludwig 
Maximilians University children’s hospitals in 2006/2007. Blasts were isolated by bone 
marrow puncture at initial diagnosis or diagnosis of relapse and isolated using Ficoll Isopaque 
(Amersham Pharmacia Biotech, Uppsala, Sweden). 
Human umbilical vein cells (HUVECs) were prepared by digestion of umbilical veins with 
0.1 g/l of collagenase A [89]. 
3.4 Cell culture 
All cell lines were cultivated at 37oC, in 5 % CO2 atmosphere in media complemented with 
serum and additional supplements (see Table 3). The suspension cell lines were maintained at 
the density below 1 x 106. All adherent cell lines were passaged after reaching 80-90 % 
confluency. Primary leukemia cells and fresh isolated PMBCs were used for experiments 
immediately after isolation, whereas HUVECs were used up to passage number 3. L3.6pl cell 
line was used up to passage number 30 as this cell line was established first after passage 
number 14 [88]. All other cell lines were used up to passage 20 to avoid mutations. 
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Table 3 Cell lines and maintaining medium  
Cell line Medium Serum Supplements Antibiotics 
S-Jurkat (J16) RPMI 1640 10 % FCS gold 1 % pyruvate  
R-Jurkat  RPMI 1640 10 % FCS gold 1 % pyruvate  
FADD -/-Jurkat  RPMI 1640 10 % FCS gold 1 % pyruvate  
Caspase-8 -/-
Jurkat  
RPMI 1640 10 % FCS gold 1 % pyruvate  
Caspase-9 -/-
Jurkat  
RPMI 1640 10 % FCS gold 
heat inactivated 
1 % pyruvate  
pBabe-Jurkat RPMI 1640 10 % FCS gold 
heat inactivated 
1 % pyruvate 1µg/ml 
puromycin every 
3rd passage 
XIAP-Jurkat RPMI 1640 10 % FCS gold 
heat inactivated 
1 % pyruvate 1µg/ml 
puromycin every 
3rd passage 
Bir3/Ring-Jurkat RPMI 1640 10 % FCS gold 
heat inactivated 
1 % pyruvate 1µg/ml 
puromycin every 
3rd passage 
Neo-Jurkat RPMI 1640 10 % FCS gold 1 % pyruvate 1mg/ml  
G418 every 5th 
passage 
Bcl-xl Jurkat RPMI 1640 10 % FCS gold 1 % pyruvate 1mg/ml 
G418 every 5th 
passage 
Bcl-2 Jurkat RPMI 1640 10 % FCS gold 1 % pyruvate 1mg/ml 
G418 every 5th 
passage 
MDA-MB-231 DMEM with high 
glucose 
10 % FCS gold 
heat inactivated 
  
LNCAP RPMI 1640 15 % FCS gold 
heat inactivated 
  
PancTu1 DMEM with high 
glucose 
10 % FCS gold 
heat inactivated 
 1 % P/S 
L3.6pl DMEM with high 
glucose 
10 % FCS gold 
heat inactivated 
1 % pyruvate 
1 % nonessential 
amino acids 
 
 
PMBC RPMI 1640 10 % FCS gold  1 % pyruvate 1 % P/S 
HUVEC Endothelial 
growth medium 
10 % FCS gold 
heat inactivated 
Supplement® 1 % P/S; 1 % 
Amphotericin B 
 
HEK-239 DMEM without 
phenol red 
10 % FCS gold 
heat inactivated 
1 % glutamine 1 % P/S 
 
3.5 Splitting and seeding for experiments 
Suspensions cells were splitted every three days to a concentration 0.5 - 0.8 x 105 cells/ml. 
For experiments, cells were seeded in 96- or 24-well plates at a cell number of 5 x 105 
cells/ml and stimulated the next day. In some cases, cells were seeded at cell number of 7 x 
106 cells /ml and stimulated after 4-5 hrs.  
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Adherent cell lines were grown as monolayer in 75 cm2 flasks coated with 0.001 % collagen 
G (Biochrom AG, Berlin, Germany). Cells were splitted after reaching 70-80 % confluency. 
For experiments, cells were seeded at a cell number of 5 x 104 – 8 x 104 cells/cm2 and left 
over night for attaching to the surface. The Trypsin/EDTA (T/E) solution was used to detach 
the cells from the plastic surface. Briefly, the medium was removed from the flask or well 
plate, cells were washed with PBS to eliminate the rest of the old medium and a sufficient 
amount of T/E was added. Cells were shortly incubated in the cell culture incubator and the 
enzymatic reaction was stopped by adding new medium. 
The cell density and viability was determinate using ViCELLTM cell viability analyzer 
(Beckman Coulter, Krefeld, Germany). 
 
Trypsin-EDTA (T/E) 
Trypsin  0.5 g 
Na2EDTA 0.2 g 
PBS  ad 1,000 ml 
 
PBS 
NaCl  7.2 g 
Na2HPO4  1.48 g 
KH2PO4  0.43 g 
H2O   ad 1,000 ml 
PBS+ 
NaCl   8.0 g 
KCl   0.2 g 
Na2HPO4   1.15 g 
KH2PO4   0.2 g 
MgCl2x6H2O   0.1 g 
CaCl2x2H2O   0.1 g 
H2O   ad 1,000 ml 
3.6 Freezing and thawing 
From all cell lines nitrogen stocks were prepared. After centrifugation for 10 min. at 
180 x g, 4°C the pellet was resuspended using freezing medium (70 % normal medium 
for each cell line, 10 % DMSO and 20 % additional FCSgold) to a concentration of 2-
3x106 cells/ml. 1.5 ml of the cell suspension were transferred into cryovials and stored 
overnight at -20°C. Afterwards, cells were stored at -85°C or transferred into liquid 
nitrogen for long time storage. 
For thawing, cells were quickly defrozen in the water bath and diluted with 10-15ml 
pre-warmed medium. Subsequently, cells were centrifuged for 10 min. at 180 x g to 
remove the DMSO and transferred into new medium. Cells were cultivated at least for 
4-5 days before they were used for experiments.  
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4 Cytotoxicity measurement (MTT assay) 
The MTT assay is a colorimetric method to measure cell survival and cytotoxicity of 
tested substances. In healthy cells, the mitochondrial dehydrogenase converts the yellow 
tetrazolium salt (MTT) into violet formazan. This reaction is proportional to the cell 
number and viability of the cells in the sample [90]. 
Cells were seeded into 96-well plates (100µl/well) as described in 3.5 and stimulated for 
the indicated times with the indicated compounds. Afterwards, 10µl MTT solution 
(5mg/ml in PBS) per well was added and cells were incubated for 1-2 hours. To 
dissolve the formazan crystals in the cells, 190µl DMSO were added per well and cells 
were incubated at room temperature under gentle agitation for one hour. The absorption 
was measured in the Tecan microplate reader (SunriseTM, Crailsheim, Germany) at 550 
nm. Untreated cells were set at 100 % viability. 
5 Proliferation measurement 
The crystal violet assay is a quantitative method to measure the cell number and 
proliferation. The crystal violet dye is absorbed in the nuclei of cells and the amount is 
proportional to the cell number. 
Cells were seeded into 96-well plates (100µl/well) as described in 3.5 and stimulated for 
the indicated times. Afterwards, medium was discarded and 100µl crystal violet solution 
(0.5 % crystal violet in 20 % methanol) per well was added. Cells were incubated for 10 
min under agitation. The dye was removed by washing with H2O and subsequently the 
plate was air dried. The crystal violet was dissolved from nuclei with destaining 
solution (0.1 M sodium citrate in 50 % ethanol or with 0.1 % SDS). The absorption was 
measured on the Tecan at 550 nm. The untreated cells were set at 100 % viability.  
6 Light and fluorescence microscopy 
Light microscopy is a convenient method for detecting morphological changes in the 
dying cell, such as cell shrinkage as well as cell blebbing and cellular swelling. Other 
features of the apoptotic cell like chromatin condensation can be detected after Hoechst 
33342 application in the fluorescence microscope. Hoechst 33342 is a cell permeable, 
vital dye which intercalates into the DNA. In contrast to healthy cells, nuclei from 
apoptotic cells are fragmented and DNA is strongly condensed resulting in the emission 
of intense blue signals. 
Cells were seeded as described and stimulated for the indicated time. Afterwards, cells 
were monitored with a Zeiss Axiovert 200 microscope (Zeiss, Oberkochen, Germany) 
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connected to a Imago-QE camera system (Till Photonics, Gräfelfing, Germany) with or 
without Hoechst 33342 (5µg/ml) staining. 
7 Flow cytometry 
Flow cytometry allows multiparameter analysis of single particles suspended in a 
stream of liquid in a very short time. Each particle (e.g. cell) individually passes a laser 
beam, gets illuminated and can be characterized due to its physical properties such as 
size, granularity and fluorescence. 
To move cells through a laser beam one after another, the principle of hydrodynamic 
focusing is applied (see Figure II.2). The sample is injected into a stream of sheath fluid 
within the flow chamber, where the sheath fluid accelerates the particles and restricts 
them to the center of the sample core. 
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Figure II.2 Principles of the hydrodynamic focusing (from [91]) 
In the flow chamber the suspension of single cells emerges from the sample needle into a surrounding 
sheath fluid moving with greater velocity. The sheath fluid accelerates the particles, restricts them to the 
center of the sample core and forces them to travel one by one in the central portion of the fluid. 
 
When particles pass the laser beam the light is scattered and the forward scatter (FSC) is 
measured in line with the laser beam and is proportional to the cell size. The sideward 
scatter (SSC) is measured from perpendicular light scattering and is proportional to the 
amount of inclusion within particles. Beyond these properties, fluorescence can be 
measured. Simultaneously, if the particles e.g. cells have their own fluorescence source 
(e.g. cells transfected with GFP) or were stained with fluorochromes (e.g. propidium 
iodide) fluorescence occurs. The scattered and fluorescence light is collected by lenses 
and forwarded to the appropriate detectors. 
II Materials and Methods 
27 
 
All measurements were performed on a FACSCalibur (Beckton Dickinson, Heidelberg, 
Germany) with a 488nm argon laser. 
The PMBCs and primary leukemic blasts were stimulated as indicated directly after 
isolation and examined for cell death by forward/side scatter analysis in FACscan after 
48 hours. Apoptotic cells were defined as smaller and more granular cells in comparison 
to control cells. 
 
Sheath fluid 
NaCl  8.12 g 
KH2PO4 0.26 g 
Na2HPO4 2.35 g 
KCl  0.28 g 
Na2EDTA 0.36 g 
LiCl  0.43 g 
Na-azide 0.20 g 
H2O  ad 1,000 ml 
pH 7.37 
7.1 Nicoletti assay 
The Nicoletti assay is a rapid method to evaluate changes of cellular DNA amount and 
integrity. Besides, the method allows monitoring of the cell size and granularity changes 
within a cell population. Originally, the method was introduced by Nicoletti et al. [92]. 
Cells get permeabilized with Triton-X-100 and incubated with propidium iodide. 
Cells were seeded as described in 3.5 and stimulated for the indicated times. 
Afterwards, cells were harvested and centrifuged for 10 min. at 600 x g, 4°C. The 
supernatant was discarded and the cell pellet was washed with ice cold PBS, the 
centrifugation procedure was repeated and the pellet was resuspended in hypotonic 
fluorescence solution (0.1 % sodium citrate, 0.1 % Triton-X-100) containing 50µg/ml 
propidium iodide. After 2 hrs or overnight incubation at 4°C the cells were analyzed in 
FACS with CellQuest Pro software. The cells left to the G0/G1 peak were considered as 
apoptotic cells (sub.G0/G1, see also Figure II.3). 
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Figure II.3 Data analysis of the Nicoletti assay with CellQest Pro software 
Histogram plot (left insert) or dot plot (right insert) from untreated control cells (A), cells stimulated for 
24 hrs with 500nM etoposide (B) or 2µM etoposide (C). The sub G0/G1 area is defined as apoptotic.  
8 Western blot 
Western blot is a common method to analyze the proteins in a cell lysate. Proteins are 
solubilized and boiled at 95°C in the presence of SDS (for denaturation) and DTT or 2-
mercaptoethanol (for reduction of disulfide bounds). So prepared samples are loaded on 
polyacrylamide gels were proteins are separated towards their molecular weight in the 
electric field. Afterwards, proteins are transferred onto a membrane and the protein of 
the interest is detected with a specific antibody. 
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8.2 Preparation of samples 
8.2.1 Whole lysate preparation  
 
Lysis buffer  
30 mM  Tris-HCl, pH 7.5 
150 mM  NaCl 
2 mM  EDTA 
1 %  Triton X-100 
 Complete™ 
 
 
 
Lysis buffer for phosphorylated proteins 
50 mM Hepes 
50 mM NaCl 
  5 mM Na2EDTA 
10 mM Na4P2O7 
50 mM NaF 
  1 mM Na3VO4 
  1 %  Triton-X-100 
PMSF 
CompleteTM 
 
For experiments, cells were prepared as described (see 3.5). At least 3ml of the cell 
suspension were pooled and centrifuged for 10 min. at 400 x g, 4°C. The pellet was 
washed with 1ml ice cold PBS and incubated for 0.5 hrs with the appropriate lysis 
buffer. Afterwards, the suspension was centrifuged for 10 min. at 10,000 x g, 4°C and 
the supernatant was collected in new tubes. One part was used for determination of 
protein concentration (see chapter 8.4); the rest was diluted with Laemmli buffer (4 
parts of the lysate, 1 part of the buffer) and boiled for 5 min at 95°C. Samples were used 
immediately or stored at -20°C. 
 
Sample buffer (5 x) 
3.125 M Tris-HCl, pH 6.8 100 µl 
Glycerol   500 µl 
SDS 20 %   250 µl 
DTT 16 %   125 µl 
Pyronin Y 5 %   5 µl 
H2O    ad 1,000 µl 
8.3 Preparation of cytosolic and mitochondrial 
fractions 
In the apoptotic process the compartmentation of mitochondrial proteins such as 
cytochrome c, smac/DIABLO, Omi/HtrA2 and others plays a pivotal role. After 
mitochondria permeabilization, these proteins are release into the cytosol and induce the 
apoptotic cascade. To investigate the release of proteins from mitochondria, cells were 
permeabilized using buffer containing digitonin. Digitonin binds to cholesterol and 
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forms micropores in the membranes. Thus, the hypotonic buffer cytosol fraction is 
eluted, whereas organelles remain within the cell. 
 
Permeabilization buffer (pH 7.2) 
Mannitol 210 mM 
Sucrose 70 mM 
Hepes pH 7.2 10 mM 
Na2EGTA 0.2 mM 
Succinate 5 mM 
BSA 0.15 % (w/v) 
Digitonin  60 µg/ml 
 
For experiments, cells were prepared as described (see 3.5). At least 3ml of the cell 
suspension were pooled and centrifuged for 10 min. at 360 x g at 4°C. The pellet was 
washed with 1ml ice cold PBS and incubated for 20 min with 100µl of permeabilization 
buffer. The cytosolic fraction was obtained by centrifugation of the cell suspension at 
360 x g (4°C, 10 min) and the supernatant was cleared from any remaining cell 
fragments at 13,000 x g (4°C, 10 min). The pellet of the first centrifugation after 
permeabilization contains mitochondria, other organelles and membranes were 
resuspended in 0.1% Triton-X 100 in PBS (100µl) and lysed for 15 min on ice. The 
supernatant of a subsequent centrifugation step (13,000 x g, 4°C, 10 min) constitutes the 
mitochondria-enriched fraction. A part of the lysate was used for determination of 
protein concentration (see chapter 8.4) and the rest was diluted with Laemmli buffer (4 
parts of the lysate, 1 part of the buffer) and boiled for 5 min at 95°C. Probes were used 
immediately or stored at -20°C.  
8.4 Protein quantification 
The Bradford method [93] was used for protein quantification. This method is based on 
the binding of the dye Coomassie Brilliant-Blue to proteins. The dye absorption 
maximum shifts from 465 nm to 595 nm after protein binding and the absorption is 
measured at 595 nm. To determine the protein concentration, samples with known BSA 
content are used as calibration curve. 
Briefly, the protein samples were diluted 1:10 in water, 10µl of this dilution and from 
BSA calibration curve were pipetted in a 96-well plate and incubated for 5 min with 
190µl of 5 times diluted RotiR-Quant (Roth, Karlsruhe, Germany). Absorbance was 
measured at 592 nm in a microplate absorbance reader (SunriceTM, Tecan, Crailsheim, 
Germany). 
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8.5 SDS-PAGE 
 
Stacking gel 
PAA solution 30 %  1.7 ml 
1.25 M Tris-HCl pH 6.8  1 ml 
SDS 10 %   100 µl 
H2O    7 ml 
TEMED   20 µl 
APS    100 µl 
 
Separating gel (10 %) 
PAA solution 30 %  5 ml 
1.5 M Tris-HCl pH 8.8  3.75 ml 
SDS 10 %   150 µl 
H2O    6.1 ml 
TEMED   15 µl 
APS     75 µl 
 
Equal amounts of the protein lysates were separated by discontinuous denaturizing 
SDS-PAGE according to the method introduced by Laemmli [94]. Sodium dodecyl 
sulphate (SDS) is used to solubilize the proteins upon binding to hydrophobic parts. 
Thereby protein secondary and tertiary structures are destroyed. Further unfolding is 
achieved by the reducing agent dithiothreitol (DTT), which cleaves disulfide bonds. 
Proteins get highly negative charged by SDS and are though drawn towards the anode 
in an electric field. Therefore, the proteins are separated solely by their size in the 
polyacrylamide gel. This discontinuous electrophoresis system consists out of two 
layers: the stacking gel, where the proteins are concentrated and the separating gel, 
where the proteins are separated. The polyacrylamide (RotiphoreseTM Gel 30, Roth, 
Karlsruhe, Germany) concentration in separating gel varies depending on the molecular 
weight of the proteins of interest. 
 
Acrylamid concentration  Proteins  
7.5 % 60-120 kDa 
10 % 70-30 kDa 
12 % 50-20 kDa 
15 % 10-45 kDa 
 
Electrophoresis buffer 
Tris base  3 g 
Glycine   14.4 g 
SDS   1 g 
H2O   ad 1,000 ml 
 
 
To determine the molecular weight, samples were compared with prestained broad 
range molecular weight marker (MBI-Fermentas, St. Leon-Rot, Germany). 
Electrophoresis was performed using the vertical Mini Protean III system (BioRad, 
Munich, Germany). Electrophoresis was run at 100 V for 21 min for stacking of 
proteins and at 200 V for 35-40 min for the separation of proteins in the electrophoresis 
buffer. 
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8.6 Western blotting and detection 
 
Tank buffer (5 x)  
Tris base 15.2 g 
Glycine 72.9 g 
H2O  ad 1,000 ml 
 
Tank buffer (1 x)  
Tank buffer (5 x) 200 ml 
Methanol 200 ml 
H2O  ad 1,000 ml 
Tank blot technique was used for protein transfer from gels onto nitrocellulose blotting 
membranes (Hybond™-ECL™, Amersham Biosciences, Freiburg, Germany) or PVDF 
blotting membranes (Immobilion-P, Millipore, Schwalbach, Germany). Membranes 
were activated in 1 x blotting buffer for 10 min and transfer sandwiches were assembled 
as follows: 
 
sandwich holder cathode side 
wetted pad 
blotting paper 
gel 
membrane 
blotting paper 
wetted pad 
sandwich holder anode side 
 
Sandwiches were inserted into a transfer device (Mini Trans-Blot®, BioRad, Munich, 
Germany) and transfer was performed in electrophoresis chamber filled up with 1 x 
transfer buffer at 4°C at 100V for 60-90 min or at 23 V overnight. 
After transfer membranes were incubated with 5 % non fat milk (BioRad, Munich, 
Germany) in TBS-T and subsequently with diluted antibody of interest for 2 hrs at RT 
or over night at 4°C under gentle shaking. 
 
TBS-T 
Tris base  3 g 
NaCl   11.1 g 
Tween  20  1 ml 
H2O   ad 1,000 ml 
 
Afterwards, membranes were washed 3 times for 10 min with TBS-T and incubated 
with secondary antibody conjugated to horseradish peroxidase for 1 hour. The 
membrane was washed 3 times for 10 min with TBS-T, all steps concerning membrane 
incubation were prepared upon gentle agitation. Proteins were visualized using the ECL 
solution. The enzyme horseradish peroxidase (HRP) catalyzes the oxidation of luminol 
in the presence of H2O2. After 1 min of incubation of membranes with ECL solution 
luminescence was detected by exposure of membranes to an X-ray film and developed 
with a Curix 60 Developing system (Agfa-Gevaert AG, Cologne, Germany). 
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Table 4 Primary antibodies 
Antibody Isotype Dilution Company  Order number 
Actin Mouse IgG 1:1,000 Milipore MAB1501R 
Caspase 2 Mouse IgG1 1:1,000 Transduct.Lab/BD 611022 
Caspase 3 Rabbit IgG 1:1,000 Santa Cruz sc-7148 
Caspase 8 Mouse IgG2b 1:1,000 Upstate 05-477 
Caspase 9 Rabbit IgG 1:1,000 Cell Signaling 9502 
Cytochrome c Rabbit IgG 1:1,000 Cell Signaling 4272 
Cytochrome c oxidase Mouse IgG2a 1:1,000 Molecular Probes A6403 
HtrA2/Omi Rabbit IgG 1:1,000 RD Systems AF1458 
PARP Mouse IgG1 1:100 Oncogene AM30 
Smac/DIABLO Rabbit IgG 1:500 Biozol BZL 00676 
XIAP mouse IgG1 1:250 Transduct.Lab/BD 610717 
 
Table 5 Secondary antibodies 
Antibody Dilution Company Order number 
Goat anti-mouse IgG1: HRP 1:1,000 Biozol BZL04266 
Goat anti-mouse IgG: HRP 1:1,000 Santa Cruz sc-2005 
Goat anti-mouse IgG2a: HRP 1:1,000 Southern Biotech Assoc. 1080-05 
Goat anti-rabbit: HRP 1:10,000 BioRad 172-1013 
Alexa Fluor® 680 Goat anti-mouse IgG 1:10,000 Molecular Probes A-21057 
 
Alexa Fluor® 680 Goat anti-mouse IgG is directly labeled with infrared (IR) 
fluorophore with emission at 700 nm. Proteins of interest were detected using Odyssey 
imaging system (Li-COR Biosciences GmbH, Bad Homburg, Germany). 
 
ECL solution  
Tris HCl, pH 8.5 1 ml 
1M Luminol 50 µl 
1M p-coumaric acid 22 µl 
H2O2 3 µl 
H2O 9ml 
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8.7 Membrane stripping 
In certain cases the PVDF membrane was reprobed with other antibodies which have 
approximately the same molecular weight as the first detected antibody. In this case 
membrane was incubated for 10 min at room temperature with 0.5 % NaOH or for 30 
min at 50°C in the stripping buffer. Subsequently membrane was blocked with 5 % non-
fat milk for one hour and incubated with the next antibody of interest. 
 
Stripping buffer 
Tris-HCl pH 6.8   62.5 mM 
SDS    2 % 
2-mercaptoethanol  100 mM 
8.8 Staining of gels and membranes  
For the visual control of the Western Blot procedure the gels were stained for 10 min 
with Coomassie Blue solution and subsequently bleached with destaining solution. The 
membranes were stained with 0.2 % Ponceau S (Sigma, Taufkirchen, Germany) 
solution and destained with TBS-T. 
 
Coomassie staining solution 
Coomassie Blue 3 g 
Glacial acetic acid 100 ml 
Ethanol   450 ml 
H2O   ad 1,000 ml 
Coomassie destaining solution 
Glacial acetic acid 100 ml 
Ethanol   333.3 ml 
H2O ad   1,000 ml 
9 Caspase activity assay 
Caspase activity can be analyzed in Western blot analysis by the detection of active 
cleavage products (see chapter 8). Another method to assess the caspase activity is 
based on the ability of caspases to specifically cleave their substrates. The peptide-based 
small substrates with a tetrapeptide sequence carrying the preferred caspase consensus 
sequence (see chapter I.6.2.3) are coupled to a fluorogenic reporter, which produces a 
fluorescence signal upon cleavage.  
Cells were prepared as described in 3.5 and stimulated with compounds. Cells were 
collected by centrifugation, washed with ice cold PBS and stored with 70µl/sample lysis 
buffer at -85°C over night. Afterwards, lysate were centrifuged (10,000 x g, 4°C), 
supernants were collected and incubated with caspase substrate (Bachem, Bubendorf, 
Germany) in a 96-well plate. The reading was performed in a plate-reading 
multifunction photometer (Spectrafluor PLUS, Tecan, Crailsheim, Germany). The 
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activity was calculated from the difference between fluorescence in the 0 point and after 
1 or 3 hrs of substrate incubation for caspase-3 and-9, respectively. Protein 
concentration of the samples was used for normalization. 
 
Lysis buffer for caspase activity 
5 mM MgCl2 
1 mM Na2EGTA 
0.1 % Triton-X-100 
25 mM HEPES, pH 7.5 
10 Clonogenic survival assay 
The clonogenic survival or colony formation assay is an in vitro method to investigate 
the long term effects of drugs on cell survival. Moreover, it can be examined in this test 
if the substances are able to kill the whole cell population, what is of high interest for 
the anti-cancer therapy. 
Suspension cells were seeded in 24-well plates as described in 3.5 and stimulated for 1-
4 hrs. Afterwards, cells were washed with PBS, replaced in new medium, counted and 
diluted to a concentration of 5 x 105/ml. 0.1 ml of this suspension was diluted with 0.9 
ml of clonogenic assay medium (20 % methocult, 40 % FCSgold, 40 % normal 
medium). Cells were seeded in 96-well plates (100µl cell suspension/well) and kept 
under normal growth conditions. After seven days a picture of each well was taken and 
colony number was counted (at least 5 cells in each colony). 
Adherent cells were seeded in 6-well plates (2 x 104 cells/well) and stimulated as 
indicated for 24 hrs. Afterwards, cells were washed two times with PBS+, supported 
with new medium and allowed to grow for six days. Afterwards, cells were stained with 
crystal violet (0.5 % crystal violet in 20 % methanol) for 10 min., the unbound crystal 
violet was subsequently removed by washing with water and the plates were air dried. 
Intracellular crystal violet was solved and absorption at 550 nm was measured. The 
untreated cells were set at 100 % viability.  
11 Reporter gene assay 
Firefly luciferase is widely used as a reporter to study gene expression. Light is 
produced by converting the chemical energy of luciferin oxidation through an electron 
transition, forming the product oxyluciferin. The enzyme catalyzes the luciferin 
oxidation using ATP and Mg2+ as co-substrates. The generated flash of light can be 
measured on a luminometer. 
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HEK-293 cells were seeded at a concentration of 4 x 106 cells/100 mm dish. The next 
day, Ca2+-phosphate transfection was performed. Cells were co-transfected with 2.8 µg 
of a plasmid containing 5.7 kB of the human NF-κB promoter driving a firefly 
luciferase gene (pNF-κB-Luc, Stratagene, LaJolla, CA, USA) and 90 µg of a β-
galactosidase plasmid (pβ-Gal, 6.82 kB, Promega, Mannheim, Germany). Transfection 
efficiency was controlled by transfecting pEGFP (Clontech, Mountain View, USA). 
After 6 hrs cells were washed with PBS+ and allowed to grow over night to grow. Cells 
were seeded in 24-well plates at the concentration of 1 x 105 cells/well and allowed to 
attach over night. Cells were stimulated with increasing concentrations of T8 or with 50 
µM pyrrolidine dithiocarbamate (PDTC) for 0.5 hour following stimulation with 1ng/ml 
TNFα for the next 5.5 hrs. Afterwards, cells were washed with PBS+, 100µl lysis buffer 
(Promega, Mannheim, Germany) per well was added and samples were frozen at -85°C 
over night.  
Lysate were incubated for 15 min under gentle agitation and subsequently, 50µl of 
lysate/sample were transferred into white 96-well plates. Luciferase activity was 
measured on Orion II Microplate Luminometer (Berthold Detection Systems, 
Pforzheim, Germany) using luciferase assay buffer. 
As a control, β-galactosidase activity measurement was performed in a plate-reading 
multifunction photometer (Spectrafluor PLUS, Tecan, Crailsheim, Germany) at 505 nm. 
Briefly, 20µl of cell lysate from luciferase assay was transferred into 96-well plates and 
180 µl of substrate buffer was added (200µl of 50nM CPRG, 20 µl β-mercaptoethanol 
in 20ml Z-buffer). The enzyme activity was calculated as the difference between 
fluorescence in the 0 point and after 16 hrs and was used for luciferase activity 
normalization. 
 
Luciferase assay buffer  
D-Luciferin 470 µM 
Coenzym A 270 µM 
DTT 33.3 mM 
ATP 530 µM 
MgSO4 2.67 mM 
Tricine 20 mM 
EDTA 0.1 mM 
 
Z-buffer  
Na2HPO4 x2H2O        60 mM 
NaH2PO4 x H2O 40 mM 
KCl 10 mM 
MgCl2 x 6H2O 10 mM 
H2O ad 500ml 
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12 TaqMan reverse-transcriptase-polymerase chain 
reaction  
RNA was isolated from Jurkat leukemia cells with the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) following the manufacturer´s protocol. RNA purity was confirmed 
by the 260/280 nm ratio and its integrity was visualized by agarose gels. Total RNA (2 
µg) was reverse-transcribed using TaqMan® Reverse Transcriptase Reagents (Applied 
Biosystems, Foster City, USA). Experiments were performed employing the ABI 7300 
Real-Time PCR System (Applied Biosystems, Foster City, USA) using the TaqMan® 
Universal PCR Master Mix Reagents Kit as recommended by the manufacturer. 
Ribosomal RNA (18S rRNA) was used as endogenous control. XIAP and 18s rRNA 
primer and probes were purchased as pre-designed TaqMan® Gene Expression Assays 
by ABI (Applied Biosystems, Foster City, USA). 
13 Transformation of bacteria and plasmid purification 
The Bir2 domain (residues 124-237 with Fesik mutation C202A C213G [64])with N-
term 8 x His-tag and the Bir3 domain of XIAP (residues 252-348) with N-term 6 x His-
tag plasmids, both in pET-15b Vector (Novagen, Darmstad, Germany) were kindly 
provided by Guy Salvesen (Burnham Institute for Medical Research, La Jolla, CA, 
USA). 
For transformation, 100µl of a solution containing the competent E.coli DHα5 strain 
were incubated for 30 min on ice with 5µl of each plasmid, followed by incubation at 
42°C for 30 sec. Subsequently, bacteria were placed on ice for 1-2 min and cell 
suspension was diluted with 900µl LB Medium (20g Lennox L Broth Base 
(Invitrogen)/l H2O) and incubated for 2 hrs on the Thermomixer comfort (Eppendorf, 
Hamburg, Germany). 50µl of bacteria suspension were spread onto agar plates (15 g 
Lennox Agar (Invitrogen)/l H2O) and incubated over night at 37°C. LB medium and 
agar plates were supplemented with 100 mg/ml ampicillin (Calbiochem). 
Colonies were picked from the agar plates, inoculated into 2-3 ml of LB medium and 
grown in a thermoshaker over night. Plasmids were isolated with EndoFree QIAprep 
Spin Miniprep Kit (Qiagen, Hilden, Germany) according to provided instruction. The 
quality of the plasmid purification was analyzed by agarose gel electrophoresis. 
Subsequently, bacteria cultures were expanded in 100 ml of LB medium and plasmid 
purification was prepared using EndFree Plasmid Maxi Kit (Qiagen). The plasmids 
were dissolved in endotoxin free H2O and the DNA concentration was determined with 
NanoDrop ND-1000 Spectrophotometer (PeqLab Biotechnologie GmbH, Erlangen, 
Germany). Plasmids were stored at -20°C.  
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From bacteria a glycerol stock was prepared as following: 750µl bacteria suspension 
was diluted in 250µl glycerol and shock frozen in liquid nitrogen. The prepared stocks 
were stored at -85°C.  
14 Fluorescence polarization assay 
Fluorescence polarization experiments were performed in collaboration with Martin 
Gräber in the group of Dr. Thorsten Berg from the Department of Molecular Biology at 
the Max Planck Institute of Biochemistry, Martinsried, Germany.  
The fluorescence polarization assay is a fast and sensitive method for the screening of 
large chemical libraries in the search for binding partners to the targets of interest. For 
this reason the method is widely used in drug discovery. It based on the molecular 
weight which affects the polarization of fluorescence emission. The fluorescence 
polarization is relatively low when the fluorescence labeled molecule is small and high 
when fluorescence label is attached to large molecules. This increase in the polarization 
of the emitted fluorescence could also be observed after binding of small, fluorescence 
labeled molecules (e.g. peptides) to a large binding partner (e.g. protein domain) [95, 
96]. The competition binding assay allows the detection of inhibitors (competitors) of 
the fluorescence labeled ligand and its binding partner. In our case it was used for 
pharmacophore modeling hypothesis validation.  
XIAP-Bir3 (aa 238-353; based on NCBI GenBank entry U45880) in pET28a (Novagen 
Darmstad, Germany) and artificial smac-derived peptide AbuRPFK-(FAM)-NH2 
(published by Nikolovska-Coleska et al. [97]) were used in the assay. Binding 
experiments were performed in 384-well, black flat bottom plates (Corning, Lowell, 
USA) using an Ultra Evolution reader (Tecan, Crailsheim, Germany) as described by 
Schust and Berg [96]. 
 
FP assay buffer 
Hepes pH 7.5  10 mM 
EDTA   1 mM  
NaCl   50 mM  
NP-40   0.1 % 
DTT   1 mM 
 
Test compounds were prediluted in DMSO and incubated with 160 nM XIAP-Bir3 
protein for 1 hour at room temperature. Afterwards, fluorescence-labeled peptide 
(AbuRPFK-(FAM)-NH2) at a final concentration of 10 nM in fluorescence polarization 
(FP) assay buffer was added. The final concentration of DMSO in the assay was 10 %. 
Binding curves were fitted with SigmaPlot (SPSS Science Software GmbH). 
Measurements were taken at point 0 and after 1h (see Figure II.4). 
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Test compound in DMSO (serial dilution)
Bir3 protein in FP buffer (160 nM)
Time
t=-1h Measurement at t=0h
AbuRPFK-(FAM)-NH2  (10nM)
Measurement at t=1h
 
Figure II.4 Preparation of fluorescence polarization measurement 
160nM XIAP-Bir3 protein was incubated with the test compound in Eppendorf tubes at RT for 1 hour 
(t=-1h) prior addition of the smac-derived peptide AbuRPFK-(FAM)-NH2 (final concentration 10 nM). 
The measurement was taken immediately at point 0 (t=0) and after 1 hour (t=1h). 
15 Nuclear magnetic resonance analysis 
The NMR analysis was performed in collaboration with Anders Frieberg (group of Prof. 
M. Sattler from the Institute of Structural Biology, Helmholtz Zentrum München and 
Chair of Biomolecular NMR, Technical University Munich, Germany). 
Nuclear magnetic resonance (NMR) spectroscopy is a one of the main techniques to 
obtain structural data about molecules and their interactions in high resolution. The 15N 
isotope has a net spin ½ making them suitable for nuclear magnetic resonance and for 
that reason the protein labeling with this isotope is a common method for NMR 
experiments. 
15N labeled proteins were prepared by growing the bacteria (Rosetta BL21, Novagen, 
Darmstad, Germany) transformed with appropriate plasmid in the minimal medium 
(M9) supplemented with 1g/l 15NH4Cl as the sole nitrogen source to produce uniformly 
15N-labeled protein [98]. Proteins were purified with nickel-nitrilotriacetic acid columns 
(Qiagen, Hilden, Germany) and eluted with 330µM imidazole. For measurement elution 
buffer was exchange into Bir2 buffer (20 mM Tris pH 8.3, 50 µM Zn(Cl)2, 300 mM 
NaCl, 100 mM 1-methyl-imidazole, 2 mM β-mercaptoethanol) or into Bir3 buffer (20 
mM NaP pH 6.8, 50 µM Zn(Cl)2, 300 mM NaCl, 2 mM β-mercaptoethanol). Ligand 
binding was investigated by aquaring standard 1H15N HSQC experiments after the 
exchange of H20 buffer to a buffer containing 2H2O at 298K on a Bruker 600MHz 
Avance 3 spectrometer (Bruker, Billerica, USA). The spectra were recorded with 
samples containing 100 µM of 15N labeled Bir2 or Bir3 with test compound (T8 or 
ABT-11 in DMSO) or without it. Then two spectra were compared to identify the 
chemical shifts perturbations induced by the additions of the test compound. Chemical 
shifts are expressed in dimensionless units of parts per million (ppm).  
16 Statistics 
All experiments were performed at least three times. Results are expressed as mean 
value ± SEM. Statistical analysis was performed with GraphPad PrismTM version 3.03 
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using one-way ANOVA with Bonferroni or Dunnett multiple comparison post-test or 
unpaired two-tailed Student´s T test. P values < 0.05 were considered significant. 
For primary cells specific apoptosis was calculated as [(absolute apoptosis of 
compound-treated cells – absolute apoptosis of untreated cells) / (100 – absolute 
apoptosis of untreated cells) x 100]. Synergistic effects were determined by analysis of 
the fractional product [99]. 
III Results 
41 
 
III Results 
1 Spongistatin 1 
1.1 Spongistatin 1 induces cell death in Jurkat leukemia T 
cells 
To investigate the cytotoxic effects of spongistatin 1 on Jurkat T cells the MTT test was 
performed. As shown in Figure III.1A spongistatin 1 causes a concentration dependent 
decrease in cell viability. For a better characterization of the cell death profile of spongistatin 
1 the DNA fragmentation assay according to Nicoletti was carried out. After 24 hrs exposure 
to spongistatin 1 wild type Jurkat showed a dose dependent increase in the DNA 
fragmentation (Figure III.1B). This feature is significant at the low concentration of 100pM. 
In comparison, the conventionally used cytotoxic drug etoposide needs an about 10,000 times 
higher concentration to induce the same effects. 
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Figure III.1 Spongistatin 1 induces cell death in wild type Jurkat cells 
Wild type Jurkat cells were stimulated with increasing concentrations of spongistatin 1 or with 2µM etoposide 
(ETO) for 24 hrs. A) Cell viability was quantified by MTT assay as described in “Materials and Methods”  
B) Apoptotic cells were quantified by flow cytometry as described in “Materials and Methods”. All experiments 
were carried out for three times. Bars, the ± SEM of three independent experiments performed in triplicate (**, 
P<0.01, ANOVA/Dunnett).  
 
To visualize nuclei fragmentation, cells were treated with the fluorescence dye Hoechst 
33342. The nuclei of cells 24 hrs exposed to spongistatin 1 are fragmented and chromatin is 
strongly condensed (Figure III.2). Both events are typical morphological changes in apoptosis 
(see also chapter I.5). 
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etoposideControl spongistatin 1
 
Figure III.2 Spongistatin 1 induces chromatin condensation in wild type Jurkat cells 
Fluorescence microscopy pictures of wild type Jurkat cells. Cells were left untreated (control), treated with 
200pM spongistatin 1 (spongistatin 1) or treated with 2µM etoposide (etoposide) for 24 hrs. Nuclei were stained 
with Hoechst 33342. 
 
For the following experiments spongistatin 1 was applied at a concentration of 200pM. In this 
concentration after 24 hrs stimulation spongistatin 1 caused a DNA fragmentation of about 50 
% in wild type Jurkat cells (Figure III.1B). 
Next the cells were stimulated with spongistatin 1 for a time course up to 24 hrs. The DNA 
fragmentation occurred in a time dependent manner and was significant after 16 hrs exposure 
(Figure III.3). 
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Figure III.3 Spongistatin 1 induces apoptosis in a time dependent manner 
Wild type Jurkat cells were stimulated with 200pM spongistatin 1 for the indicated times. Apoptotic cells were 
quantified by flow cytometry as described in “Materials and Methods”. The experiment was carried out for three 
times. Bars, the ± SEM of three independent experiments performed in triplicate (**, P˂0.01, ANOVA/Dunnett). 
1.2 Spongistatin 1 induces cell death in primary leukemic 
cells 
To examine the clinical relevance of spongistatin 1 in the treatment of acute leukemia the 
substance was tested on primary tumor cells obtained from children suffering from acute 
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leukemia. This part of the work was done in cooperation with the group of PD Dr. Irmela 
Jeremias (Department of Gene Vectors, Helmholz Center, Munich, Germany). To compare 
different primary cells, specific apoptosis was calculated as described in “Material and 
Methods” (chapter 16). 
After 48 hrs spongistatin 1 at a concentration of 1 nM induced cell death in 11 out of 12 (91.7 
%) samples (Figure III.4A). Most importantly, spongistatin 1 shows a minor toxicity on 
peripheral mononuclear blood cells (PMBCs) pointing to a rather selective effect on tumor 
cells. 
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Figure III.4 Spongistatin 1 induces cell death in primary leukemic cells but is low toxic for peripheral 
mononuclear cells 
Samples were analyzed for percentage of apoptotic cells using forward/side scatter in FACScan A) Primary 
leukemia cells of 12 children with acute leukemia were isolated from bone marrow and incubated with 
spongistatin 1 for 48 hrs. Each bar represents data obtained from one patient. B) Peripheral mononuclear blood 
cells were isolated as described in “Materials and Methods” and stimulated with spongistatin 1 as indicated for 
48 hrs. Bars, the mean ± SEM of three independent experiments performed in triplicate.  
 
To show the extraordinary potency of spongistatin 1, other conventionally used cytotoxic 
drugs were tested in parallel (Figure III.5). In vitro spongistatin 1 was more effective than 8 
out of 10 (80 %) drugs. Additionally, spongistatin 1 was used just in nanomolar range, 
whereas the other cytotoxic drugs were administrated at micromolar concentrations. 
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Figure III.5 Spongistatin 1 is more effective than conventional cytotoxic drugs 
Primary leukemia cells of 12 children with acute leukemia were isolated from bone marrow and incubated with 
spongistatin 1 (Spongi, 1 nM) or 6-Thioguanin (6-TG, 1 µM), Cyclophosphamid (Cyclo, 0.3 µM), Vincristin 
(VCR, 30 nM), Methotrexat (MTX, 30 µM), Prednison (Pred, 10-4 M), Asparaginase (Asp 1 U/ml), 
Dexamethason (Dexa, 10-5 M), Cytarabin (AraC, 10 µM), Etoposid (VP-16, 30 µM) or Doxorubicin (Doxo, 0.5 
µM) for 48 hrs. Samples were analyzed for percentage of apoptotic cells using forward/side scatter in FACScan. 
Bars represent mean of 12 samples ± SEM. 
1.3 Spongistatin 1 inhibits clonogenic survival of Jurkat 
leukemic T cells 
For long term analysis of the potency of spongistatin 1 in wild type Jurkat cells, clonogenic 
assay was performed. After stimulation with spongistatin 1 for just 4 hrs, Jurkat cells showed 
a strongly reduced ability to form new colonies, indicating chemotherapeutical potential of 
spongistatin 1 (Figure III.6). 
 
 
III Results 
45 
 
B C
0
50
100
%
 
Co
lo
n
ie
s
**
S1control
A
S1control
 
Figure III.6 Spongistatin 1 abrogates clonogenic survival of Jurkat T cells 
Jurkat cells were left untreated or stimulated with spongistatin 1 (S1, 200 pM) for 4 hrs and clonogenic survival 
was analyzed as described in “Materials and Methods”. Results are represented as the number of colonies 
referred to untreated cells (control). Bars, the mean ± SEM of three independent experiments performed in 
triplicate. ** P < 0.001 (ANOVA/Dunnett). Representative pictures of the experiments are shown (B, C). 
1.4 Spongistatin 1 induce caspase-dependent apoptosis 
Caspase activation is a molecular feature in the execution of the classical apoptotic program. 
To investigate if spongistatin 1-induced apoptosis is caspase-dependent the broad-range 
caspase inhibitor zVADfmk was used. Wild type Jurkat cells were pretreated with 25µM 
caspase inhibitor and stimulated with spongistatin 1 (200pM, 24 hrs) (Figure III.7). 
Interestingly, caspase inhibition led to an almost complete suppression of spongistatin 1-
induced DNA fragmentation, demonstrating the importance of caspases in this apoptotic 
process. 
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Figure III.7 Spongistatin 1 induced apoptosis is caspase dependent. 
Wild type Jurkat were left untreated (control) or pretreated with zVADfmk (25µM, 1h) and incubated with 
200pM spongistatin 1 (S1) for 24 hrs. Apoptotic cells were quantified by flow cytometry as described in 
“Materials and Methods”. Bars, the ± SEM of three independent experiments performed in triplicate (**, 
P<0.001, unpaired two-tailed t-test). 
III Results 
46 
 
The activation of the respective initiator and effector caspases was elucidated by Western Blot 
analysis (Figure III.8). The initiator caspases-8 and -9 as well as the effector caspases-3, -7 
and -2 were activated 16 hrs after stimulation with 200pM spongistatin 1, as shown by the 
appearance of the cleavage products.  
Poly-ADP-ribose-polymerase (PARP) is an important enzyme supporting the repair of single 
strand DNA-nicks. PARP cleavage (at 89 kDa) is a common feature of the apoptotic process 
and could be observed in spongistatin 1 treated cells (Figure III.8). 
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Figure III.8 Spongistatin 1 causes massive caspases activation and PARP cleavage in Jurkat cells 
Wild type Jurkat cells were treated with 200pM spongistatin 1 or 2µM etoposide (ETO) for the indicated times. 
Whole cell lysates were prepared and activation of caspase-8, -9, -2, -3, -2, -7, and PARP cleavage was assessed 
by Western blot analysis as described in “Materials and Methods”. Cleavage products are indicated by arrows. 
Ponceau S staining was used as loading control. A representative experiment out of three independent 
experiments is shown. 
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1.5 The extrinsic apoptotic pathway is not important for 
spongistatin 1 to induce apoptosis  
In order to elucidate the impact of spongistatin 1 on the extrinsic apoptotic pathway, we used 
Jurkat cells deficient in caspase-8 (caspase-8-/- cells), FADD or CD95, respectively. In 
caspase-8-/- cells and in FADD (Fas associated death domain) deficient Jurkat cells, no 
reduction of apoptosis could be detected compared to control cells (Figure III.9A). Moreover, 
apoptosis was not inhibited in the subclone R-Jurkat cells, which lack the CD95 receptor 
(Figure III.9B), further supporting the idea that spongistatin 1 acts independent of the 
classical death-receptor pathway.  
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Figure III.9 Spongistatin 1 induces apoptosis independently of the CD95 receptor, the adaptor molecule 
FADD and caspase-8 
Jurkat A3 (control cells), Jurkat caspase-8-/-, Jurkat FADD-/- cells (A) or S-Jurkat and R-Jurkat (lacking the 
CD95 receptor) (B) were treated with the indicated concentrations of spongistatin 1 for 24 hrs. Apoptotic cells 
were quantified by flow cytometry as described in “Materials and Methods”. All experiments were carried out 
three times in triplicate. Data points, the mean ± SEM of three independent experiments. 
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1.6 Caspase-9 is essential for spongistatin 1 mediated 
apoptosis  
Besides the extrinsic the intrinsic apoptotic pathway is an important way by which apoptosis 
can be trigged in cells. Caspase-9 as well as proteins released from mitochondria represents 
the central elements in this pathway (see also chapter I.128).  
To investigate the impact of caspase-9 activation on spongistatin 1 induced apoptosis, 
caspase-9 deficient Jurkat cells were used. As shown in Figure III.10 caspase-9 deficiency 
completely inhibited spongistatin 1 induced apoptosis. 
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Figure III.10 Spongistatin 1 induced apoptosis is dependent on caspase-9 
Control cells (S-Jurkat) and Jurkat caspase-9-/- cells were treated with the indicated concentrations of 
spongistatin 1 for 24 hrs. Apoptotic cells were quantified by flow cytometry as described in “Materials and 
Methods”. All experiments were carried out three times in triplicate. Data points, the mean ± SEM of three 
independent experiments. 
 
 
Moreover, in wild type Jurkat cells the activation of effectors caspases-3 and -2 could be 
observed (Figure III.8), whereas this effect is fully abolished in caspase-9 deficient Jurkat 
cells (Figure III.11). 
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Figure III.11 Caspase-9 is important for the activation of effector caspases 
Caspase-9 deficient Jurkat cells were incubated with 200 pM spongistatin 1 for the indicated times or with 
etoposide (ETO, 2µM, 24 hrs). Caspase-3 and -2 were detected by Western blot analysis as described in 
“Materials and Methods”. A representative experiment out of three independent experiments is shown. 
1.7 Mitochondria play a pivotal role in spongistatin 1 
induced cell death 
Since the intrinsic pathway seems to be important in spongistatin 1 induced apoptosis it was 
of high interest to investigate the release of proapoptotic proteins from mitochondria. 
Subcellular fractionation and Western blot analysis for cytochrome c, smac/DIABLO and 
Omi/HtrA2 was carried out. As shown in Figure III.12 spongistatin 1 induces release of 
cytochrome c, smac/DIABLO and Omi/HtrA2 from mitochondria into the cytosol after 16 
hrs. For control of fractionation quality Western blot membranes were reprobed with 
cytochrome c oxidase (COX). This enzyme of the respiratory chain is localized to the inner 
mitochondrial membrane and can be used as a mitochondrial loading control. As expected the 
COX can be detected just in mitochondrial fraction and in whole cell lysate (Figure III.12) 
confirming the proper preparation of the fractions. 
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Figure III.12 Spongistatin 1 induces mitochondrial release of cytochrome c, smac/DIABLO and 
Omi/HtrA2 
Jurkat cells were treated with 200pM spongistatin 1 for the indicated times or with etoposide (ETO, 24h, 2 µM). 
Cytosolic and mitochondrial fractions were prepared as described in “Materials and Methods”. Cytochrome c, 
smac/DIABLO and Omi/HtrA2 were detected by specific antibodies using Western blot analysis. Cytochrome c 
oxidase served as control for the quality of the extraction procedure and a whole cell lysate (L) was used to 
control the blotting quality. Ponceau S was used as loading control. A representative experiment out of three 
independent experiments is shown. 
1.8 Bcl-2 and Bcl-xl overexpression saves Jurkat cells from 
spongistatin 1 induces cell death 
Bcl-2 and Bcl-xl are important proteins for saving the mitochondria membrane integrity. 
These two antiapoptotic members of the Bcl-2 family (see also chapter I.9) inhibit the pore 
formation in OMM and the release of proapoptotic proteins into the cytosol. 
To analyze the role of Bcl-2 and Bcl-xl proteins in spongistatin 1 induced apoptosis, cells 
overexpressing the respective proteins were used. Figure III.13 shows that Bcl-xl as well as 
Bcl-2-overexpressing Jurkat cells were protected against spongistatin 1. In contrast, Neo-
Jurkat carrying empty vector and serving as control cell line showed concentration dependent 
increasing apoptosis levels. This further emphasizes the idea that spongistatin 1 induces a 
mitochondria-dependent pathway of apoptosis. 
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Figure III.13 Bcl-2 and Bcl-xl overexpression protects Jurkat cells from spongistatin 1 induced apoptosis 
Neo-Jurkat, Bcl-xl-Jurkat and Bcl-2-Jurkat cells were incubated with the indicated concentrations of spongistatin 
1 for 24 hrs. Apoptosis was quantified by flow cytometry as described in “Materials and Methods”. Data points, 
the mean ± SEM of three independent experiments. 
1.9 Spongistatin 1 induces cell death in XIAP 
overexpressing Jurkat cells 
XIAP is the most potent natural cellular inhibitor of active caspases. Many tumor cells show 
XIAP overexpression which is discussed as one of the reasons for chemoresistance in cancer 
cells [100, 101]. Since the spongistatin 1 trigged apoptosis is dependent on caspases (see also 
chapter III.1.4) it was important to investigate the influence of XIAP overexpression on the 
efficacy of spongistatin 1 to induce cell death. Interestingly, spongistatin 1 is able to 
overcome overexpression of XIAP. XIAP overexpressing cells treated with various 
concentrations of spongistatin 1 for different time points died up to the same percentage as 
wild type Jurkat cells after 24 hrs treatment. (Figure III.14). In contrast, etoposide, a widely 
used chemotherapeutic agent failed to induce cell death in XIAP overexpressing cells. 
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Figure III.14 Spongistatin 1 induces apoptosis in XIAP overexpressing cells 
Wild type (S-Jurkat) Jurkat and XIAP overexpressing (X-Jurkat) Jurkat cells were treated with different doses of 
spongistatin 1 or 2 µM etoposide for different time points. Cell death was evaluated as described in “Materials 
and Methods”. Insert: XIAP levels in S-Jurkat and X-Jurkat cells were analyzed by Western blot. The mean ± 
SEM of three independent experiments performed in triplicate is shown. 
1.10 Spongistatin 1 reduces XIAP protein level 
XIAP can be inactivated by different ways. One possibility is a decrease of protein level. 
Indeed, we observed in both, wild type and XIAP-overexpressing Jurkat cells, that 
spongistatin 1 leads to XIAP degradation, as shown in Western blot analysis in Figure 
III.15A. This down-regulation of XIAP could be due to modulation at either the 
transcriptional or posttranscriptional level. Therefore, analysis of XIAP mRNA levels using 
reverse transcription RT-PCR was performed. As shown in Figure III.15B spongistatin 1 did 
not alter XIAP mRNA expression (data by Dr. N. Barth) suggesting a post-transcriptional 
influence of spongistatin on XIAP level. 
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Figure III.15 Spongistatin 1 reduces XIAP protein level 
(A) S-Jurkat and X-Jurkat cells were left untreated (CN) or were treated with spongistatin 1 (200 pM) or 
etoposide (ETO, 2 µM) for the indicated periods of time. XIAP protein degradation was detected by Western 
blot analysis. (B) Jurkat cells were exposed to 200 pM spongistatin 1 or etoposide (ETO, 2 µM) for the indicated 
interval, after which expression of XIAP mRNA was monitored by RT-PCR as described in “Materials and 
Methods”. XIAP mRNA was normalized to 18s rRNA levels. Bars, the mean ± SEM of three independent 
experiments performed in duplicate. (ANOVA/Dunnett; n.s., not significant). 
1.11 Spongistatin 1 sensitizes Jurkat cells for 
staurosporine treatment 
To overcome the chemoresistance in cancer cells the combination therapy of different drugs is 
applied. It allows hitting the resistant cells from different sites and is often more effective than 
the treatment with a single agent. Mostly, the drugs used in such combinations are used at 
lower concentrations compared to monotherapy but achieve synergistically elevated effects on 
cell death induction. A further advantage is to minimize toxic side-effects for healthy tissue 
[102]. 
Therefore, we investigated, whether spongistatin 1 might enhance the cell death induced by 
another apoptosis inducing agent such as staurosporine. We treated wild type Jurkat cells with 
low concentrations of spongistatin 1, staurosporine and a combination of both and quantified 
apoptosis induction after 24 hrs. As shown in Figure III.16A spongistatin 1 at 50 pM is able to 
significantly enhance the cell death induced through staurosporine (5 nM). In order to 
estimate the role of XIAP degradation for the above shown synergistic effect, the 
chemosensitizing activity was analyzed in XIAP-overexpressing Jurkat cells. Indeed, 
combination of spongistatin and staurosporine synergistically (synergism was calculated as 
described in “Materials and Methods”) multiplies apoptosis. This cooperative effect is even 
stronger than in wild type cells, indicating that spongistatin is able to sensitize cells towards 
apoptosis in XIAP-overexpressing tumor cells. 
In terms of therapeutic application we investigated the effect of the combination of both drugs 
on healthy PMBCs. As shown in Figure III.16B, neither a significant increase nor synergistic 
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effects of the substances on apoptosis could be detected, suggesting a specific effect on tumor 
cells. 
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Figure III.16 Spongistatin 1 enhances staurosporine-induced cell death 
Wild type (S) and XIAP overexpressing (X) Jurkat cells as well as healthy PMBCs were treated with a low 
concentration of staurosporine (5 nM), spongistatin 1 (50 pM), or a combination of both for 24 hrs. Cell death 
was evaluated as described in “Materials and Methods”. Bars, the mean ± SE of three independent experiments 
performed in triplicate. ## P < 0.001, unpaired two-tailed t-test. 
 
Since we used a very low dose of spongistatin in combination with staurosporine to treat 
cancer cells we were interested if XIAP is degraded. Although spongistatin is not able to 
induce DNA-fragmentation in this low concentration, XIAP protein level is still slightly 
decreased (Figure III.17). In combination with staurosporine more XIAP protein is degraded, 
suggesting that the increased apoptosis levels are related to this degradation. 
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Figure III.17 Spongistatin in combination with staurosporine reduces XIAP protein level 
Wild type (S) and XIAP overexpressing (X) Jurkat cells were treated with a low concentration of staurosporine 
(5 nM), spongistatin 1 (50 pM), or a combination of both for 24  hrs and XIAP protein degradation was analyzed 
by Western blot. Ponceau S was used as loading control. A representative experiment out of three independent 
experiments is shown. 
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2 Search for XIAP inhibitors 
As mentioned above it is known from literature that XIAP overexpression confers resistance 
to apoptotic stimuli. We also could show that XIAP overexpressing cells are resistant towards 
etoposide (Figure III.14). Interestingly, spongistatin is able to overcome XIAP 
overexpression, most likely because this natural compound directly targets XIAP (Figure 
III.15). Therefore, it would be of high interest for therapeutic applications to find substances 
that directly interact with XIAP. Since random selection of compounds and subsequent testing 
in cell culture is a little promising approach the virtual screening technique was applied.  
2.1 Virtual search for XIAP inhibitors – the pharmacophore 
model 
A pharmacophore model, Hypo2-1TFQexcludvolumes7 based on the interaction of an 
antagonist of the XIAP - caspase-9 - interaction complex to the Bir3 domain was built (see 
Figure II.1; data by the group of Prof. H. Stuppner from the Institute of Pharmacy, 
Pharmacognosy at the University of Innsbruck, Austria). It consists of two donor features 
describing the ligand’s peptide nitrogens which are supposed to bind to the enzyme’s Thr308 
and Gly306, respectively. Furthermore, a hydrogen acceptor function was localized from the 
Trp323 to the ligand’s N-terminal peptide oxygen. The three hydrophobic features mimic the 
bulky tert-butyl residue of the ligand, its proline ring, and its 1,2,3,4-tetrahydronaphthalene, 
respectively. Additionally excluded volume spheres representing side chains of the protein 
and therefore inaccessible areas were included to the model. The data were implemented into 
the pharmacophore model using the Catalyst Software 4.9 (Accelrys Inc., San Diego, USA) as 
shown in Figure III.18. 
 
 
Figure III.18 Pharmacophore hypothesis from Catalyst software. 
Pharmacophore model hypothesis: green: H-bond acceptor function; violet: H-bond donor function; turquoise: 
hydrophobic spheres; black: excluded volume spheres. 
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The pharmacophore model was validated in a self made database of 30 compounds well 
known to inhibit XIAP-Bir3 interaction. To retrieve a limited number of virtual hits, a 
consensus screening was applied using the GRID-based pharmacophore model Hyp3-1G3F 
previously published by Ortuso et al. [84] and the validated pharmacophore model Hypo2-
1TFQexcludvolumes7. Consensus hits obtained by virtual screening filtering experiments of 
various databases resulted in hit rates in between 0.05 and 1.57 % (see Table 6). Out of the 
obtained virtual consensus hits some compounds were selected according to the previously 
mentioned criteria (see chapter II.2) and tested in cell culture models. 
Table 6 Consensus hits of virtually screened databases 
Database Amount of compounds Number of consensus hits Virtual hits in % 
Asinex Platinum 1104 114652 489  0.43 % 
Asinex Gold 1104 224371 129 0.06 % 
Specs 1104 216823 106 0.05 % 
Maybridge 2004 59652 31 0.05 % 
Derwent WDI_2003 63307 997 1.57 % 
NCI 123219 144 0.12 % 
2.2 Cellular models for the in vitro validation of virtual 
screening hits  
For validating the results from virtual screening, selected hit substances were tested in cell 
culture models. To create a rapid cellular screening method, four Jurkat clones were used, 
characterized by different XIAP levels as shown in Figure III.19. S-Jurkat cells (wild type 
Jurkat) and pBabe (empty vector Jurkat cells) served as the control cells. XIAP 
overexpressing Jurkat cells (X-Jurkat) as well as Bir3- and RING- overexpressing Jurkat cells 
(Bir3/RING-Jurkat) were used to verify the first virtual screening derived evidence for the 
XIAP-Bir3 to be a major target of the compound. 
To prove the relevance of XIAP-Bir3 inhibitors, the testing was extended beyond leukemia to 
other cancer cell lines including the prostate cancer cell line LNCAP, the breast carcinoma 
cell line MDA-MB-231 and two pancreatic cell lines: PancTu1 and high invasive L3.6pl cell 
line. All cell lines were verified to express XIAP, as shown in Figure III.19. 
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Figure III.19 XIAP expression in different cell lines 
Cell lysates from wild type Jurkat cells (S-Jurkat), empty vector Jurkat cells (pBabe-Jurkat), XIAP 
overexpressing Jurkat cells (X-Jurkat), Bir3/Ring overexpressing Jurkat cells, Human umbilical vein endothelial 
cells (HUVECs), LNCAP, MDA-MB-231, PancTu1 and L3.6pl cells were prepared and XIAP level was 
analyzed by Western blot. Actin was used as loading control. The upper arrow denotes full length XIAP, the 
lower one indicates Bir3/RING fragment of XIAP. A representative experiment out of three independent 
experiments is shown.  
 
2.3 The synthetic compound T8 as XIAP inhibitor 
During the virtual screening of the available databases, compound T8 was recognized as 
virtual hit and was chosen for further pharmacological tests. In order to derive a structure 
activity relationship for T8, analogues of T8 were searched. As shown in Figure III.20 twenty 
structures of the resulting hits were selected for testing according to their high value of 
similarity and their different substitution patterns. 
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Figure III.20 Structure of T8 and T8 analogues 
T8 and its analogues (T8-1 – T8-20) were obtained from Asinex Ltd (Moscow, Russia). T8 was furthermore 
synthesized and kindly provided by the group of Prof. K. T. Wanner. 
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2.3.1 T8 sensitizes different Jurkat cell lines for etoposide 
treatment 
T8 was tested in the different XIAP-Jurkat cell lines on its ability to induce apoptosis in 
combination with a low dose of etoposide. As shown in Figure III.21 T8 alone is not toxic for 
Jurkat cells but in the combination with low dose of etoposide significantly induce apoptosis 
in all four Jurkat clones. 
A
0
25
50
75
%
 
ap
op
to
tic
 
ce
lls
Wilde type Jurkat
500nM etoposide
+
+
+
+
-
- -
- 25µM T8
**
0
25
50
75
%
 
ap
op
to
tic
 
ce
lls
Vector Jurkat
**
1µM etoposide
+
+
+
+
-
- -
- 25µM T8
B
0
25
50
75
%
 
ap
op
to
tic
 
ce
lls
1µM etoposide
+
+
+
+
-
- -
- 25µM T8
*
Bir3/RING JurkatDC
co
ntr
ol
0
25
50
75
%
 
ap
op
to
tic
 
ce
lls **
1µM etoposide
+
+
+
+
-
- -
- 25µM T8
XIAP Jurkat
 
Figure III.21 T8 sensitized different Jurkat cell lines towards etoposide-induced apoptosis 
T8 was tested in wild type human leukemia Jurkat T cells (S-Jurkat), as well as in Jurkat cells stably transfected 
with empty vector (pBabe-Jurkat), full-length XIAP overexpressing cells (X-Jurkat) or the Bir3/Ring domain 
overexpressing Jurkat cells (Bir3/RING-Jurkat). Cell death was evaluated as described in “Materials and 
Methods”. Bars, the mean ± SEM of three independent experiments performed in triplicate. * P<0.05, ** 
P˂0.01, unpaired two-tailed t-test. 
2.3.2 T8 in combination with etoposide inhibits clonogenic growth 
of Jurkat cells 
To analyze the long term effects of T8 on Jurkat cells, the clonogenic assay was performed. 
Cells were stimulated for just 4 hrs with T8, etoposide or the combination of both agents. 
Subsequently, cells were washed with PBS, replaced at the defined cell number in medium 
and allowed to grow for seven days. This experiment investigates if the new agents are able to 
affect growth of all cells in the population or if a part of cells is able to form new colonies 
after removing the agents, a sign of chemoresistance. Based on the  relatively short exposition 
to the drugs the assay is also closer to the therapy situation where cytostatic drugs are applied 
just in short time. 
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T8 in combination with etoposide is able to inhibit the formation of new colonies (Figure 
III.22D). In comparison to etoposide alone, colony number in the combination is significantly 
reduced and the single cells look damaged. 
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Figure III.22 T8 in combination with etoposide strongly inhibits clonogenic survival of Jurkat cells 
Wild type Jurkat cells were left untreated (A) or treated for 1 h with 25µM T8 (B), 500nM etoposide (C) or a 
combination of both, respectively (D). After 7 days of cultivation, colonies were counted. T8 in combination 
with a subtoxic dose of etoposide significantly reduced clonogenic growth of the cells (E). Bars, the ± SEM of 
three independent experiments performed in triplicate. ** P˂0.01 unpaired two-tailed t-test. 
2.3.3 T8 derivatives 
Because T8 revealed the best test results, a structure activity relationship (SAR) study was 
performed (by the group of Prof. H. Stuppner from the Institute of Pharmacy, Pharmacognosy 
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at the University of Innsbruck, Austria). In order to derive a structure activity relationship for 
T8, analogues of T8 were searched using the Tanimoto similarity search function of the 
SciFinder program [SciFinder Scholar 2006; Help tool]. Twenty structures of the resulting 
similarity hits were selected for further testing (see also Figure III.20). Interestingly, 16 out of 
the 20 analogues were able to map with all the set features of both pharmacophore models.  
T8 derivatives were tested for their ability to induce apoptosis in combination with etoposide 
using Nicoletti assay. As shown in Figure III.23 some of them were not able to induce 
apoptosis by themselves, but show more than an additive effect on apoptosis levels in 
combination with etoposide (mostly T8-18, T8-2). T8-14 induced apoptosis alone in about 30 
% of the cell population but in combination with etoposide this effect still can be elevated. 
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Figure III.23 T8 derivatives sensitized Jurkat cells for etoposide treatment 
Cells were left untreated (control) or treated with 500nM etoposide, 25µM of the respective derivatives or a 
combination of both. Cell death was evaluated by Nicoletti assay as described in “Materials and Methods”. Bars, 
the ± SEM of three independent experiments performed in triplicate. ***˂0.001, ** P˂0.01, * P˂0.05, unpaired 
two-tailed t-test. 
 
According to its strong effects in Nicoletti assay, T8-18 was also tested for ability to inhibit 
the clonogenic growth of the cells in clonogenic assay. Jurkat cells were treated with T8-18, 
500nM etoposide or combination of both for 1 hour and then replaced into fresh medium for 
further seven days. After colony counting, T8-18 in combination with 500nM etoposide 
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showed significant decrease in clonogenic survival of wild type Jurkat cells in comparison to 
etoposide alone (Figure III.24).  
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Figure III.24 T8-18 in combination with etoposide strongly inhibits clonogenic survival of Jurkat cells 
Wild type Jurkat cells were left untreated (A) or treated for 1 h with 25µM T8-18 (B), 500nM etoposide (C) or a 
combination of both, respectively (D). After replacement into fresh methylcellulose medium, cells were 
incubated for seven days, afterwards colonies were counted. T8-18 in combination with a subtoxic dose of 
etoposide significantly reduced clonogenic growth of the cells (E). Bars, the ± SEM of two independent 
experiments performed in triplicate. *** P˂0.01 unpaired two-tailed t-test. 
 
Since T8 was the structure originally found by virtual screening all further experiments were 
done with T8. 
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2.3.4 T8 sensitizes different cancer cells for doxorubicin treatment 
To investigate if the chemosensitizing effect of T8 is limited to leukemia cells and works only 
in combination with etoposide, additional experiments were performed. The prostate cancer 
cell line LNCAP and the breast adenocarcinoma cell line MDA-MB-231 were treated with 
25µM T8 and 500nM or 600nM doxorubicin, respectively, for 48 hrs. Afterwards DNA 
fragmentation was assessed using Nicoletti assay. 
As shown in Figure III.25 T8 sensitized both cell lines for treatment with doxorubicin. 
Moreover, this effect is significant in the LNCAP cell line. 
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Figure III.25 T8 sensitizes different tumor cells to low dose of doxorubicin 
T8 was tested in prostate cancer cells LNCAP (A) or breast carcinoma cells MDA-MB-231 (B) for 48 hrs in 
combination with 500nM or 600nM doxorubicin, respectively. % apoptotic cells, percentage of cells with 
subdiploid DNA content. Bars, the mean ± SEM of three independent experiments. 
2.3.5 T8 sensitizes PancTu1 cells for TRAIL treatment 
In order to investigate the influence of T8 on different cancer cells and different stimuli, the 
pancreatic PancTu1 cell line and tumor necrosis factor-related apoptosis-inducting ligand 
(TRAIL) was chosen, since it has been reported that XIAP knockdown sensitizes pancreatic 
carcinoma cells for TRAIL treatment [103]. We can confirm these data by showing that after 
six days of cultivation the formation of new colonies is reduced in samples simultaneously 
treated with T8 and TRAIL. 
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Figure III.26 T8 sensitizes PancTu1 carcinoma cells for TRAIL treatment 
PancTu1 pancreas cancer cells were left untreated or were stimulated for 24 hrs with T8 and TRAIL as indicated. 
Afterwards, cells were washed with PBS, replaced in new medium and allowed to grow for further six days. The 
cells were incubated with crystal violet as described in “Materials and Methods”. Pictures were taken and the 
intracellular crystal violet was dissolved with destaining solution. The absorption was measured and untreated 
cells were set at 100 % viability. Bars, the mean ± SEM of two independent experiments performed in 
duplicates. 
2.3.6 T8 in combination with etoposide decreases clonogenic 
survival of pancreas cancer cells 
To investigate the long-term effects of T8 in combination with etoposide on the high invasive 
pancreatic cancer cell line L3.6pl clonogenic assay was performed. L3.6pl was derived from 
the human pancreatic adenocarcinoma cell line COLO 357 by injection into the pancreas of 
nude mice. Afterwards the spontaneous hepatic metastases were harvested and reinjected into 
the pancreas of another set of nude mice. This selection cycle was repeated three times. In 
these cells increased cell motility and expression of matrix metalloproteinase 9 (MMP-9) was 
detected [88], facts that are in line with the high metastatic profile of L3.6pl cell line. 
As shown in Figure III.27 T8 is able to sensitize the L3.6pl to etoposide treatment. After 
treatment for 1 h with the respective drugs and subsequent replacement of the cells in new 
medium for further six days, the number of cells treated with a combination of T8 and 
etoposide is strongly decreased. Moreover, 25µM and 50µM T8 alone have no effects on the 
cell viability. 
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Figure III.27 T8 in combination with etoposide reduces clonogenic survival of pancreas cancer cells 
L3.6pl cells were left untreated (control) or were stimulated for 24 hrs with T8 and etoposide (eto) as indicated. 
Afterwards, cells were washed with PBS, replaced in new medium and allowed to grow for further six days. The 
cells were incubated with crystal violet as described in “Materials and Methods”. Pictures were taken and the 
intracellular crystal violet was dissolved with destaining solution. The absorption was measured and untreated 
cells were set at 100 % viability. Bars, the mean ± SEM of three independent experiments. ***˂0.001, ** 
P˂0.01, unpaired two-tailed t-test. 
2.3.7 T8 in combination with cytotoxic drugs is not toxic for 
HUVECs 
Finally, to investigate if T8 in combination with etoposide induce apoptosis selectively in 
cancer cells or affects also non-cancer cells, HUVECs (Human Umbilical Vein Cells) were 
used. As shown in Figure III.28 T8 in combination with 2µM etoposide or 600nM 
doxorubicin showed just slight toxicity in the MTT assay in HUVECs. 
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Figure III.28 T8 with the same combination of the drugs as for tumor cells is not toxic for primary 
endothelial cells (HUVECs) 
HUVECs were left untreated or stimulated for 48 hrs with substances as indicated. Cell viability was quantified 
by MTT assay as described in “Materials and Methods”. Bars, the ± SEM of three independent experiments 
performed in triplicate. 
2.3.8 T8 reduces XIAP protein level  
Having clearly shown that the chemosensitizing effect of T8 is neither restricted to a single 
cell type nor to a single chemotherapeutic and importantly is rather selective for cancer cells, 
we were interested if XIAP is targeted by T8. To investigate the effect of T8 on XIAP protein 
expression in cells, Western blot analysis was performed. As shown in Figure III.29 T8 alone 
and in combination with etoposide reduces the XIAP protein level in both wild type and 
XIAP overexpressing Jurkat cells in a so far unknown process. 
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Figure III.29 T8 alone and in combination with etoposide reduces XIAP protein level 
S-Jurkat cells were treated with T8 (25 µM), a low concentration of etoposide (500 nM), or a combination of 
both (A) and XIAP overexpressing Jurkat were incubated with 25µM T8 (B) for indicated time points. XIAP 
protein degradation was analyzed by Western blot as described in “Materials and Methods”. Actin was used as 
loading control. A representative experiment out of three independent experiments is shown. 
2.3.9 T8 enhances etoposide induced caspase-dependent 
apoptosis 
We were further interested in the underlying signaling mechanisms leading to apoptosis 
induced by the combination of T8 and etoposide in Jurkat cells. To investigate if T8-induced 
apoptosis is caspase-dependent the broad-range caspase inhibitor zVADfmk was used. Wild 
type Jurkat cells were stimulated with T8 (25µM), 500nM etoposide or combination of both. 
Cells treated with the combination of T8 and etoposide, additionally were pretreated with 
25µM of zVADfmk. The almost complete suppression of T8 and etoposide-induced DNA 
fragmentation showed the importance of caspase in this cell death process (Figure III.30A). 
T8 was found in the virtual screening to be able to bind to Bir3. Since caspase-9 selectively 
binds to the Bir3 domain, T8 should lead to the release of free caspase from the inhibition 
complex. Subsequently, treatment with etoposide could initiate the caspase cascade. Thus, if 
indeed XIAP is affected caspase-9 should play a central role in the apoptosis induction by T8. 
Therefore, cells were pretreated with cell permeable caspase-9 inhibitor zLEHDfmk. 
Interestingly, inhibition of caspase-9 led to a suppression of the T8 and etoposide induced 
apoptosis to control level (Figure III.30B). 
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Figure III.30 T8 in combination with etoposide induces caspase-dependent apoptosis. Caspase-9 plays 
central role in this process 
Wild type Jurkat cells were left untreated (Co) or pretreated for 1 h with 25µM zVADfmk (A) or 50µM 
zLEHDfmk (B) and subsequently incubated with 25µM T8, 500nM etoposide or a combination of both for 24 
hrs. Apoptotic cells were quantified by flow cytometry as described in “Materials and Methods”. Bars, the ± 
SEM of three (A) and two (B) independent experiments performed in triplicate (***, P˂0.001, unpaired two-
tailed t-test). 
2.3.10 T8 in combination with etoposide increase caspase activity 
To examine the effects of T8 on caspase activity the fluorescence based caspase activity assay 
was performed. It is based on the ability of activated caspase to cleave specific substrates in 
the cell lysate. The whole procedure also allows to test the caspase activity independently of 
pharmacological inhibitors and to exclude its possible side effects on the cells. 
As expected for a XIAP inhibitor, caspase activities induced by a subtoxic dose of etoposide 
are significantly increased by T8 co-treatment. As shown in Figure III.31A the initiator 
caspase-9 activity is 1.5-fold higher as in comparison to control cells. Since caspase-3 is 
activated by caspase-9 also this effector caspase activity was increased as shown in Figure 
III.31B. After 16 hrs of stimulation, the caspase-3 activity is 13.5-fold higher as in the control 
cells. 
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Figure III.31 T8 increases initiator and effector caspase activity 
Wild type Jurkat cells were left untreated or treated with 25µM T8, 500nM etoposide or a combination of both 
agents for the indicated time periods. Fluorescence measurements of caspase-9 (A) and caspase-3 (B) activities 
were performed as described in “Material and Methods”. Protein concentration was used for normalization. Bars, 
the ± SEM of three independent experiments performed in triplicate. ** P˂0.01, * P˂0.05, unpaired two-tailed t-
test. 
2.3.11 T8 in combination with etoposide activates the intrinsic 
caspase cascade 
The activation of the respective initiator and effector caspases was elucidated by Western Blot 
analysis. As shown in Figure III.32 T8 in combination with etoposide caused an activation of 
the initiator caspase-9 as well as the effector caspase-3 after 16 hrs. At this time point 
etoposide alone does not affect the cleavage of caspases. Furthermore, PARP cleavage at 89 
kDa can be detected after stimulation for 16 hrs with a combination of both compounds. 
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Figure III.32 T8 in combination with etoposide activates caspases and induces PARP cleavage in Jurkat 
cells 
Wild type Jurkat cells were treated with 25µM T8 or 0.5µM etoposide or a combination of both for the indicated 
times. Whole cell lysates were prepared and activation of caspase-9, -3, and PARP cleavage was assessed by 
Western blot analysis as described in “Materials and Methods”. Cleavage products are indicated by arrows. 
Actin was used as loading control. A representative experiment out of three independent experiments is shown. 
2.3.12 Fluorescence polarization assay 
The fact that T8 is able to sensitize chemoresistant XIAP overexpressing cells to etoposide 
induced apoptosis and that this apoptosis is dependent on caspase-9 are strong signs of T8 
being a XIAP -binding and -inhibiting compound. In order to assure this assumption and to 
prove the virtual screening concept, fluorescence polarization experiments were performed. 
These assays were done in collaboration with Martin Gräber in the group of Dr. Thorsten 
Berg from the Department of Molecular Biology at the Max Planck Institute of Biochemistry, 
Martinsried, Germany. 
The substance ABT-11 is a validated XIAP-Bir3 inhibitor [81] and served as a positive 
control in the experimental setting. As shown in Figure III.33A ABT-11 is able to displace the 
fluorescein labeled smac-derived peptide AbuRPFK-(FAM)-NH2 from the Bir3 domain in a 
dose dependent manner with the IC50 of approximately 50 nM after one hour. 
Unexpectedly, T8 showed no changes in the binding between Bir3 and the fluorescein labeled 
peptide AbuRPFK-(FAM)-NH2 (Figure III.33B). These findings implicate that Bir3 is not the 
primary target of T8. 
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Figure III.33 Effect of ABT-11 (A) and T8 (B) on binding of AbuRPFK-(FAM)-NH2 to Bir3 measured by 
fluorescence polarization assay 
Serial dilutions of ABT-11 (A) and T8 (B) were prepared in assay buffer. Smac-derived peptide AbuRPFK-
(FAM)-NH2 and Bir3 was added, and the % binding of the AbuRPFK-(FAM)-NH2 to Bir3 was assessed at the 
start point of measurement (t=0h) and after 1h (t=1h), respectively. Error bars represent SD. 
2.3.13 NMR analysis 
To confirm the data from the fluorescence polarization assay and to obtain additional 
information about T8 targets, NMR analysis was performed. The analysis was done in 
collaboration with Anders Frieberg (group of Prof. M. Sattler) from the Institute of Structural 
Biology, Helmholtz Zentrum München and Chair of Biomolecular NMR, Technical 
University Munich, Germany. 
Bir3 and Bir2 proteins were labeled with 15N and the spectrum of free protein and protein 
with ABT-11 (positive control) and T8, respectively was collected at the Bruker 600 Mhz 
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Avance 3 spectroscope (Bruker, Billerica, USA). Overlay of two 1H15N HSQC spectra of the 
Bir3 domain with ABT-11 (green) and without it (red) is shown in Figure III.34A. Several 
residues in XIAP-Bir3 protein were affected by the binding of ABT-11 (chemical shift 
perturbations in the spectrum of free protein and protein incubated with ABT-11). As shown 
in Figure III.34B T8 does not affect the Bir3 domain of XIAP. 
A
 
B
 
Figure III.34 NMR spectrum from Bir3 domain with ABT-11 and T8 
Overlay of 1H15N-HSQC spectra of free XIAP Bir3 (100µM, red) and upon addition of equal amount of ABT-11 
(A, green) or seven fold molar excess of T8 (B, green), respectively.  
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Since the Bir3 and Bir2 share nearly 40 % identity [54] we performed additional NMR 
experiments using the Bir2 domain of XIAP. As shown in Figure III.35A ABT-11 binds to 
the Bir2 domain of XIAP. The chemical shift perturbations in many residues (red versus 
green) of this domain identify ABT-11 as a strong binding partner of Bir2 domain. In 
comparison, the overlay of two spectra from Bir2 domain with (green) and without T8 (red) 
(Figure III.35B) did not show any chemical shifts perturbations, showing that T8 is not a Bir2 
domain binding compound. 
A
 
B
 
Figure III.35 NMR spectrum from Bir2 domain with ABT-11 and T8 
Overlay of 1H15N-HSQC correlation spectra of free Bir2 domain (100µM, red) and upon addition of the equal 
amount of ABT-11 (A, green) or T8 (B, green), respectively. 
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2.3.14 T8 inhibits NF-κB activation 
Although T8 is not able to bind either isolated Bir3 or Bir2 domains it shows the same 
biological activities as other XIAP inhibitors in vitro [104, 105]. Therefore, we were 
interested in the impact of T8 on the other XIAP domains. It is known that XIAP dimerization 
induces the recruitment and activation of TAB1 to Bir1 domain. TAB1 is an upstream adapter 
for the activation of the TAK1 kinase linked to the NF-κB pathway. Smac/DIABLO indirectly 
is able to disrupt this assembly [67]. 
As shown in Figure III.36 TNFα (1ng/ml) induces an increase of NF-κB activity which dose-
dependently was reduced by pretreatment with T8. Moreover, 100µM T8 reduced the NF-κB 
activity to the same level as the positive control, pyrrolidine dithiocarbonate (PDTC, 50µM). 
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Figure III.36 T8 inhibits NF-κB promoter activity 
HEK-293 cells transfected with NF-κB promoter driving a luciferase reporter gene were left untreated (control) 
or stimulated with increasing concentrations of T8 as indicated. After 0.5 hrs, 1ng/ml TNFα was added to the 
culture and cells were left for further 5.5 hrs. Cells were lysed and analyzed for luciferase activity as described in 
“Materials and Methods”. β-galactosidase was used for normalizing the luciferase activity. Bars, the mean ± 
SEM of three independent experiments performed in triplicate. ** P˂0.01, * P˂0.05, unpaired two-tailed t-test. 
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IV Discussion 
1 Spongistatin 1  
Natural compounds play a major role as a source for the discovery of new anticancer agents 
[3]. Currently a significant number of marine compounds is evaluated in clinical trials [106]. 
Spongistatin 1 is a new marine compound which shows extraordinary potency in the NCI 
cancer cell line panel [13]. In this work spongistatin 1 was examined in the treatment of 
leukemia. Although there is some progress in therapy of leukemia which leads to an increase 
of the survival rates of the patients, more effective treatments are still needed [107]. Thus, 
spongistatin 1 can be a promising novel therapeutic agent for the treatment of leukemia. 
1.1 Spongistatin 1 is a potent new anticancer agent 
This work identifies spongistatin 1, a marine natural product, as a powerful anti-leukemic 
compound. Spongistatin 1 induces apoptosis in Jurkat T leukemia cells already in the 
picomolar range. Additionally this compound shows long term effects on leukemic cells as it 
significantly reduces clonogenic survival. 
Most importantly, spongistatin 1 is also active in patient leukemic cells. Spongistatin 1 
induces apoptosis in 11 out of 12 primary tumor cell samples of children suffering from acute 
leukemia. As no in vivo data concerning spongistatin 1 toxicity exist so far, the maximal 
tolerable plasma concentration of spongistatin 1 remains elusive. Spongistatin 1 is even more 
potent than 8 out of 10 already clinically applied cytotoxic drugs (such as 6-thioguaninin, 
methotrexate, etoposide or AraC). Moreover, spongistatin 1 only slightly affects healthy 
peripheral mononuclear blood cells. 
All these aspects together with the successfully completed synthesis [108] make spongistatin 
1 an exceptional new natural drug and a promising anticancer agent. 
1.2 Spongistatin 1 induces caspase dependent cell death 
in leukemic cells 
As shown by using the caspase inhibitor zVADfmk, spongistatin 1 induced cell death depends 
on caspases. In detail, we found that caspase-9 deficient cells are resistant to spongistatin 1, 
whereas the lack of caspase-8 has no impact on the spongistatin 1-induced apoptosis. In this 
context, for spongistatin 1 the intrinsic apoptotic cell death pathway seems to be more 
important than the extrinsic one. Moreover, the results show a strong involvement of 
mitochondria in the apoptotic process. Spongistatin 1 triggers apoptosis via the release of 
mitochondrial factors such as cytochrome c, smac/DIABLO or Omi/HtrA2 and the 
subsequent activation of caspases. Overexpression of Bcl-2 or Bcl-xl rescues cells from 
spongistatin 1 induced death, additionally confirming the relevance of the intrinsic pathway. 
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1.3 Spongistatin 1 overcomes XIAP caused resistance 
Apoptosis is essential in maintaining tissue homeostasis. Therefore, dysfunctions in this 
process lead to disorders such as cancer. At a fundamental level, cancer occurs or progresses 
because malignant cells fail to undergo apoptosis either spontaneously or in response to 
chemotherapy. As caspases play the central role in the execution of apoptosis, the barrier in 
the activation of caspases leads to apoptosis resistance [109]. The most potent caspase 
inhibitor from the IAP family, X chromosome-linked IAP (XIAP) prevents both, the 
activation of the initiator caspase-9 as well as the activation of the effector caspases-3 and -7. 
[63, 110, 111]. XIAP is highly expressed in several classes of cancer [112, 113] and correlates 
with poor survival in childhood de novo acute myeloid leukemia [8]. Therefore, the blockade 
of XIAP function is an attractive strategy for restoring apoptosis sensitivity in neoplasia. 
Consequently, a variety of small molecule inhibitors of XIAP have been developed such as 
polyphenylurea derivatives, the natural compound embelin and others [5, 114]. 
This work introduces spongistatin 1 as a highly promising experimental drug in this context. 
Spongistatin, in contrast to other chemotherapeutics such as etoposide, is able to induce cell 
death in XIAP overexpressing Jurkat cells. After treatment with spongistatin 1 XIAP 
overexpressing cells show slower, time dependent DNA fragmentation in comparison to wild 
type Jurkat cells, but after 24 hrs the levels of the fragmented DNA is comparable in both 
clones. In contrast XIAP overexpressing Jurkat cells stimulated with etoposide show just a 
minor response to the treatment in comparison to wild type cells. We can show that 
spongistatin 1 had no effect on XIAP mRNA level, hence the reduced XIAP protein level is 
most likely the result of enhanced posttranscriptional degradation. XIAP is effectively 
degraded at the protein level in spongistatin 1 treated wild type and XIAP overexpressing 
Jurkat T cells. This indicates XIAP to be the possible target of spongistatin 1 in leukemia 
cells. Spongistatin 1 could be involved in XIAP autoubiquitination and proteasomal 
degradation of XIAP [66]. However, the indirect XIAP degradation induced by spongistatin 
1-mediated release of smac/DIABLO, Omi/HtrA2 from mitochondria as well as the activation 
of caspases or cathepsins is also possible [70, 72, 73, 115]. The exact mechanism for XIAP 
degradation after spongistatin 1 treatment has to be elucidated. 
1.4 Spongistatin 1 sensitizes leukemic cells for 
staurosporine treatment 
The most important feature in terms of a therapeutic benefit of spongistatin 1 is the 
sensitization of leukemic cells for other chemotherapeutics. The synergistic interactions 
between anticancer agents applied in combination provide a greater benefit than the additive 
effects of each agent applied alone. Beside improved efficacy there is also the hope to 
minimize side effects of the chemotherapeutics [102]. It is proven that XIAP targeting in 
addition to conventional treatment improves cancer therapy. The XIAP antisense AEG35156 
is already evaluated in a clinical phase I/II in combination with carboplatin and paclitaxel in 
patients suffering from advanced non-small cell lung cancer [116]. 
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In this work we are presenting that spongistatin 1 at a very low concentration sensitizes 
leukemic cells towards staurosporine-induced apoptosis. The combination of the two agents 
shows high synergistic effects. Interestingly, the extent of cooperative effect of spongistatin 
and staurosporine was much more pronounced in XIAP-overexpressing cells in compare to 
wild type Jurkat cells. Spongistatin 1 is able to decrease the XIAP level in wild type Jurkat 
cells and the combination with staurosporine leads to a significant degradation of XIAP in 
XIAP overexpressing cells, being in line with increased apoptosis levels in X-Jurkat cells 
after treatment with the combination of these two substances. These facts indicate that XIAP 
degradation is a possible underlying mechanism for the synergistic effects of spongistatin 1 
and staurosporine. The healthy blood cell experiments indicate that the combination of both 
agents does not have any additional negatives effects on the cells in comparison to 
monotherapy with staurosporine. 
However, regarding the attractivity of XIAP as a drug target overcoming chemoresistance it is 
of note that XIAP regulates apoptosis in a context-dependent manner: XIAP inhibition has 
been shown to fail to sensitize leukemia cells treated with etoposide [117] or in breast 
carcinoma cells upon treatment with carboplatin or doxorubicin [118]. Spongistatin 1 showed 
only a synergistic effect on leukemic cell death when cells were treated with low dose of 
staurosporine, but not with etoposide (data not shown). This may be due to the different mode 
of action of the both agents: etoposide activates the apoptosis via the mitochondrial pathway 
whereas staurosporine is a protein kinase inhibitor. Furthermore, spongistatin 1 as well as 
etoposide activates the mitochondria-mediated apoptotic pathway. This possibly causes the 
overlapping of the cytotoxic effects and finally results in just additive or even antagonistic 
results. The same ineffective results were found in the diffuse large B-cell lymphomas 
(DLBCLs) where caspase-9 is constitutively activated [119]. After combination of the 
experimental XIAP inhibitor 1396-12 with etoposide there was no significant increase in 
apoptosis levels, because the intrinsic pathway was already activated and could not further get 
activated by etoposide [120]. The same situation occurs in spongistatin 1 treatment. 
Mitochondria and intrinsic apoptotic pathway already are activated by spongistatin 1 and thus 
etoposide treatment is irrelevant for the apoptotic effects. Staurosporine in contrast, as a 
protein kinase inhibitor, induces apoptosis by multiple pathways in leukemia cells [121] 
which can contribute to the synergistic effects observed after treatment with spongistatin 1. 
1.5 Concluding remarks and future directions 
The present work has demonstrated that spongistatin 1 is a potent new compound in the 
treatment of leukemia, whereas toxicity on normal blood cells is low. Spongistatin 1 induces 
apoptosis in primary tumor cells of children suffering from acute leukemia. When used in low 
nanomolar concentrations, spongistatin causes apoptosis more efficiently than most of 
clinically used, cytotoxic drugs applied with 300–10,000 times higher concentrations. 
Spongistatin 1 induces apoptosis in leukemia Jurkat T cells and inhibits long time survival of 
these cells. The induced apoptosis involves the mitochondrial pathway and is caspase 
dependent. Spongistatin 1 kills XIAP-overexpressing, apoptosis resistant, leukemic cells and 
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degrades XIAP protein which might be the reason for its sensitizing effect when combined 
with staurosporine. Three major questions remain to be answered and require further studies: 
(i) Is XIAP the primary target of spongistatin 1 and if so, in which way does this 
natural compound degrade XIAP? 
(ii) Is there a correlation between the XIAP levels in patient samples and the treatment 
outcome? 
(iii) Are there other cytotoxic drugs which in combination with spongistatin 1 lead to 
synergistic apoptosis elevation? Are there criteria which can predict a good 
outcome of combination? 
 
2  T8 as a XIAP inhibitor 
XIAP overexpression frequently is observed in cancer chemoresistance and leads to poor 
patient’s outcome [8, 112, 113]. For this reason, approaches antagonizing XIAP haven´t lost 
their attractivity in search for potent antitumor strategies. XIAP antisense oligonucleotides as 
well as ectotopic expression of smac/DIABLO, an endogeneous inhibitor of IAPs provided 
the proof of principle by enhancing the efficacy of chemo-and/or radiotherapy of cancer [81, 
122-125]. Consequently a variety of small molecule inhibitors of XIAP have been developed 
such as polyphenylurea derivatives [114], the natural compound embelin and others [5, 114] 
which have been shown to directly induce apoptosis of tumor cell lines in culture and 
sensitize cancer cells to chemotherapeutic drugs. 
The Bir3 domain of the XIAP is involved in the inhibition of caspase-9 activation [63]. This 
interaction of Bir3 and caspase-9 was the basis for the pharmacophore model generation. 
During the virtual screening of the available databases, molecules that fulfill set features in 
the pharmacophore model were recognized as virtual hits and evaluated in the in vitro screen 
comprising wild type Jurkat, empty vector, XIAP overexpressing and Bir3/RING 
overexpressing Jurkat leukemia T cells. From the panel of substances T8 was chosen as the 
most promising one and analyzed in detail. 
2.1 T8 in combination with etoposide significantly 
increases cell death in leukemia cells  
T8 alone is not toxic for leukemia Jurkat T cells but in combination with a subtoxic dose of 
etoposide significantly increases apoptosis in all four Jurkat clones (wild type, empty vector, 
XIAP overexpressing and Bir3/RING overexpressing Jurkat). The sensitizing effect in XIAP 
and Bir3/RING overexpressing clones support first evidence that Bir3 is a major target for T8. 
As XIAP inhibitor, T8 is not expected to be cytotoxic by itself as shown for other XIAP 
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inhibitors such as LBW242 or smac peptides [104, 105]. For this reason etoposide treatment 
serves as inducer for the apoptotic events. In combination with etoposide T8 is able to 
decrease the clonogenic growth of wild type Jurkat cells in the long term assay. 
2.2 T8 analogues 
In order to find the optimal chemical structure for XIAP inhibition a structure activity 
relationship (SAR) study was performed. Twenty analogues of T8 were tested for their ability 
to induce apoptosis in leukemic cells. T8-18 and T8-2 were the most potent compounds in this 
panel. In combination with etoposide they caused even more apoptosis in Jurkat cells than the 
parental T8. Also in long term clonogenic assay T8-18 shows comparable effects with T8. 
It seems that elongation of the T8 molecule by a methylene group between the piperidine ring 
and ring Y (as seen in T8-18) results in a distinct increase of apoptotic activity. Furthermore a 
halogen in ring X seems rather not desirable since the most potent compounds do not exhibit 
such substituent. Exchange of the F atom (T8) by a Br moiety (T8-2) in ring Y has rather no 
effect. Additional information about analogues solubility or pharmacokinetic attributes like 
membrane permeability are required to explain the different sensitizing effects of the 
respective compounds. 
2.3 T8 sensitizes different cancer cells for cytotoxic drugs 
As shown in this work T8 also sensitized other cancer cell lines for various cytotoxic drugs. 
There were reports concerning the sensitizing effects of XIAP suppression and DNA 
intercalating doxorubicin treatment [126, 127]. The two cell lines LNCAP prostate cancer 
cells and MDA-MB-231 breast carcinoma cells show an increase in apoptosis level after 
treatment with the combination of T8 and doxorubicin in comparison to doxorubicin alone. 
As reported in the past XIAP plays a pivotal role in the chemoresistance of LNCAP to 
chemotherapy [128]. This fact correlates with the significant increase in apoptosis level after 
treatment with XIAP inhibitor T8 and doxorubicin. 
The expression of XIAP protein in pancreatic cancer cells is elevated in comparison to non-
malignant pancreas tissue. Furthermore, pancreatic cancer is one of the most aggressive 
human tumors with poor survival prognosis [129]. Thus, the inhibition of XIAP has become a 
very promising approach in pancreas cancer therapy [103, 130]. 
We can show that the pancreas cancer cell line PancTu1 is sensitized for Tumor Necrosis 
Factor Related Apoptosis Inducing Ligand (TRAIL) upon co-treatment with our XIAP 
inhibitor. T8 enhances TRAIL-induced inhibition of proliferation in the long term clonogenic 
assay. Our findings agree with earlier studies where stable downregulation of XIAP in 
PancTu1 cells induced TRAIL-mediated apoptosis [87], or where smac mimetics sensitized 
for TRAIL induced apoptosis in breast cancer cells [103, 125, 131]. Furthermore, in the long 
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term clonogenic assay, the high invasive pancreas cancer cell line L3.6pl [88] shows a 
significant reduction of new colonies formation after T8 and etoposide treatment. 
2.4 T8 is not toxic for the healthy cells 
T8 alone is not toxic for Human Umbilical Vein Endothelial Cells (HUVECs) as evaluated in 
cytotoxicity assays. XIAP expression is frequently elevated in cancer cells [100, 112] making 
it a good target for cancer therapy with low side effects for the healthy tissue. T8 even in the 
same combination with the cytotoxic drugs (etoposide and doxorubicin) as for tumor cell 
treatment shows just slight toxic effect in HUVEC cells. Due to these data T8 seems to be a 
target- specific compound which affects cancer cells. Low cytotoxic effects in healthy cells 
make T8 a new attractive chemosensitizing agent. 
2.5 T8 reduces XIAP protein level and contributes to 
caspase dependent apoptosis 
T8 alone and in combination with etoposide reduces the XIAP protein level both in wild type 
and XIAP overexpressing Jurkat cells via a so far unknown process. Caspases, calpains and 
smac/DIABLO could be involved in XIAP degradation or ubiquitination [70, 72, 73] and 
XIAP level also could be regulated at the transcriptional level. To explore the exact 
mechanism for XIAP degradation after T8 treatment additional experiments have to be 
performed. 
As shown in this work T8 in combination with non toxic doses of etoposide induces caspase 
dependent cell death in leukemic cell. After pretreatment with the broad spectrum caspase 
inhibitor no apoptotic cell death can be detected. Pretreatment with the specific caspase-9 
inhibitor also completely reduces apoptosis. The measurement of the caspase activity shows 
that caspase-9 as well as caspase-3 is strongly increased upon stimulation with T8 and 
etoposide. The same effects can be confirmed by Western blot analysis. Additionally the 
cleavage of DNA-repair associated nuclear enzyme poly-(ADP-ribose)-polymerase (PARP), a 
common feature of the apoptotic process [132], can be observed. T8 alone is not able to 
induce apoptosis. It seems that etoposide is required for the initial activation of caspase-9 after 
T8 induced XIAP inactivation. There exist various other reports describing XIAP inhibitors to 
enhance caspases activation and PARP cleavage. XIAP knockdown using antisense 
AEG35156 or short-hairpin RNA (shRNA) increases TRAIL-mediated caspase activation 
[103, 116, 118] and small molecule smac-mimics enhance etoposide-mediated caspase 
activation [131]. These data correlate well with our results. 
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2.6 T8 does not bind to Bir3 or Bir2 domains of XIAP 
In order to prove if T8 binds to Bir3 domain of XIAP, a sensitive and quantitative 
fluorescence polarization-based assay was performed. The known XIAP-Bir3 inhibitor ABT-
11 was used as a positive control [81]. Unexpectedly, T8 does not show direct binding affinity 
to the Bir3 domain, whereas ABT-11 concentration dependently was able to bind to the Bir3 
domain of XIAP (IC50 0.05µM). 
This data was supported by experiments using nuclear magnetic resonance (NMR) 
heteronuclear single quantum coherence spectroscopy (HSQC). Upon T8 incubation no 
changes in the Bir3 domain could be observed whereas ABT-11 strongly affected Bir3. 
Since the Bir3 and Bir2 share nearly 40 % identity [54] we performed additional experiments 
showing that Bir2 was affected by ABT-11 but not by T8. 
In summary it was unexpected that T8 does not directly bind to either the Bir3 or the Bir2 
domain, although the pharmacophore modeling and virtual screening predicted T8 to fit into 
Bir3. In addition, in cellular assays T8 shows a strong chemosensitizing effect correlating 
very well with published data from other XIAP inhibitors. These effects could result from 
indirect binding of T8 to the Bir2 or Bir3 domain, e.g. to the XIAP surface close to both 
domains in such a way which excludes the binding between XIAP and caspase-9 or -3 or 
which changes the XIAP conformation. It is also possible that XIAP is not the target of T8, 
but T8 inhibits other proteins upstream of XIAP e.g. the protein kinase Akt. Akt is shown to 
protect XIAP ubiquitination [133]. If Akt is inhibited by T8, XIAP can be degraded in the 
proteasome. To verify these hypotheses additional experiments with full length XIAP have to 
be performed. 
2.7 T8 reduces NF-κB activation 
XIAP is involved in the modulation of diverse signaling pathways such as cell motility or 
copper homeostasis [51, 52]. The XIAP-NF-κB pathways connection was discovered in the 
late ’90s in endothelial cells [76], but only recently the detailed mode of NF-κB activation 
through XIAP has been elucidated [67]. It involves the Bir1 domain dimerization and its 
interaction with TAB1. Smac/DIABLO can negatively affect the NF-κB activation by 
interaction with the Bir2 and the Bir3 domains. According to these facts we were interested in 
the impact of T8 on NF-κB activation. In this work we present that in fact T8 negatively 
regulates this pathway. It was shown that inhibition of NF-κB sensitized carcinoma cells to 
apoptosis induced by etoposide, doxorubicin or TRAIL [134, 135]. We could also observe 
sensitizing effects of T8 in combination with etoposide, doxorubicin or TRAIL, which 
suggests a connection between XIAP - NF-κB pathways. Although smac/DIABLO does not 
directly interact with Bir1, it antagonizes Bir1/TAB1 interaction by steric exclusion. T8 could 
act in a similar way and hinder Bir1/TAB1 complex formation. NF-κB inhibition might be a 
mechanism responsible for the sensitizing effects of T8 treatment. Up to now this is highly 
speculative and has to be confirmed in future experiments. 
IV Discussion 
83 
 
2.8 Concluding remarks and future directions 
T8 was chosen from the hit entities of a pharmacophore-based virtual screening as a 
promising new agent to overcome the XIAP caused chemoresistance of cancer cells. In 
cellular assays, T8 induces significant enhancement of apoptosis in combination with 
cytotoxic drugs such as etoposide, doxorubicin or TRAIL. The triggered cell death is caspase 
dependent with caspase-9 which activates the effector caspase-3 and the cleavage of DNA 
repair enzyme PARP playing a major role. T8 also inhibits NF-κB activation which might be 
a result of Bir1/TAB1 complex disruption. Moreover, T8 does not show any toxic effects on 
healthy HUVEC cells. 
The hypothesis of T8 to be a compound that binds to the Bir3 domain could not be supported 
by fluorescence polarization assays and NMR analysis. 
Three major questions remain to be answered and require further studies:  
(i) What is the cellular target of T8? Is it XIAP or do other proteins play a pivotal 
role? To what extent does NF-κB inhibition contribute to the sensitizing effects of 
T8? 
(ii) Which upstream proteins lead to the activation of caspases? 
(iii) Are the in vitro effects of T8 also relevant in vivo? 
Up to now we can say that T8 is a promising new agent to overcome XIAP caused 
chemoresistance in combination with other cytotoxic drugs. Furthermore T8 is not toxic per 
se, making it an appropriate agent in multi-drug chemotherapy. 
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V Summary 
This work presents two new agents: spongistatin 1 and T8 as potent compounds to overcome 
XIAP caused chemoresistance in different cancer cells. 
SPONGISTATIN 1 
The natural marine compound spongistatin 1 is a potent new agent to induce cell death in 
primary tumor cells of children suffering from acute leukemia. It is even more potent as 8 out 
of 10 clinically applied cytotoxic drugs. Most importantly, it shows selectivity towards cancer 
cells since it does not affect healthy mononuclear blood cells. 
Based on the presented data we propose the mechanism of spongistatin 1 induced cell death as 
illustrated in Figure V.1. Spongistatin 1 induces caspase-9 dependent cell death which 
involves the release of cytochrome c, smac/DIABLO and Omi/HtrA2 from mitochondria. 
Overexpression of Bcl-2 or Bcl-xl saves leukemia cells from spongistatin 1 induced apoptosis. 
Moreover, spongistatin 1 proves beneficial to overcome the XIAP related chemoresistance in 
leukemia cancers and is a promising new agent for the treatment of cancer cells in 
combination with other cytotoxic drugs. 
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Figure V.1 Proposed mechanism of spongistatin 1-induced apoptosis 
 
 
 
 
V Summary 
85 
 
T8 AS A XIAP INHIBITOR 
T8 is a synthetic compound found by virtual screening for XIAP-Bir3 inhibitors. Indeed T8 is 
able to restore the ability of etoposide to induce apoptosis in XIAP and Bir3/RING 
overexpressing chemoresistant Jurkat T cells. As shown in Figure V.2 T8 enhances etoposide-
mediated caspase activation. T8 activity is not limited to leukemia cells, this chemosensitizing 
agent is also active in breast, prostate and pancreas cancer cells in combination with 
etoposide, doxorubicin or TRAIL. 
Although T8 shows benefits in XIAP overexpressing cancer cells, neither Bir2 nor Bir3 seem 
to be a main direct targets of T8. Interestingly, T8 is able to suppress NF-κB activation, a 
process connected to the Bir1 domain of XIAP. Further studies will elucidate molecular 
targets responsible for T8 biological activity. 
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Figure V.2 Schematic illustration of T8 mode of action 
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VII Appendix 
1 Abbreviations 
 
AIF  Apoptosis inducing factor 
ANOVA  Analysis of variance between groups 
Apaf-1  Apoptotic protease-activating factor-1 
APS  Ammonium persulfate 
ATP/dATP  Adenosine-5´-triphosphate/2´-desoxyadenosine-5´-triphosphate 
Bcl  B-cell lymphoma 
BH  Bcl-2 homology 
BIR  Baculoviral IAP repeats 
BSA  Bovine serum albumin 
CAD  Caspase-activated DNase 
CARD  Caspase recruitment domain 
CED  Cell death abnormality 
cIAP  Cellular inhibitor of apoptosis 
CPRG  Chlorophenol Red-β-D-galactoside 
DD  Death domain 
DED  Death effector domain 
DIABLO  Direct IAP binding protein with low pI 
DISC  Death inducing signaling complex 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DR  Death receptor 
DTT  Dithiothreitol 
ECL  Enhanced chemoluminescence 
EDTA  Ethylene diamintetraacetic acid 
EGTA  Ethylene glycol-bis(2-aminoethylether) tetraacetic acid 
EndoG  Endonuclease G 
ER  Endoplasmic reticulum 
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FACS  Fluorescence activated cell sorter 
FADD  Fas-associated death domain 
FasL  Fas ligand 
FCS  Fetal calf serum 
FL  Fluorescence 
FP  Fluorescence polarization 
GI  Growth inhibition 
HEK Human embryonic kidney 
HEPES  N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HFS  Hypotonic fluorochrome solution 
HRP  Heteronuclear single quantum coherence spectroscopy 
HSQC  Heteronuclear single quantum coherence spectroscopy 
HtrA2  High temperature requirement protein A2 
HUVEC Human umbilical vein cell 
IAP  Inhibitor of apoptosis protein 
IBM  IAP-binding motif 
ICE  Interleukin-1β converting enzyme 
IL  Interleukin 
IMM  Inner mitochondrial membrane 
IRES  Internal ribosome entry site 
JNK  c-Jun N-terminal kinase 
kDa  Kilo Dalton 
ki Inhibitory constant 
LB  Lennox L Broth Base 
LRR leucine-rich repeats 
ML-IAP  melanoma IAP 
MMP  Mitochondrial membrane permeabilization 
MMP-9  Matrix metalloproteinase 9 
mRNA  Messenger RNA 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NAIP  Neuronal apoptosis inhibitory protein 
NCCD Nomenclature Committee on Cell Death 
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NCI  National Cancer Institute 
NF-κB  Nuclear Factor-κB 
NMR Nuclear magnetic resonance 
NOD nucleotide-binding oligomerization domain 
OMM  Outer mitochondrial membrane 
PAA  Polyacrylamide 
PARP  Poly(ADP-ribose) polymerase 
PBS  Phosphate buffered saline 
PCD  Programmed cell death 
PDB Protein Data Bank 
PDTC Pyrrolidine dithiocarbamate 
PI  Propidium iodide 
PIDD  p53 inducible protein with a death domain 
PMSF  Phenylmethylsulphonylfluoride 
ppm  parts per milion 
PS  Phosphatidylserine 
RING Really interesting new gene 
ROS Reactive oxygen species 
RT  Room temperature 
SDS  Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SE  Standard error 
SEM  Standard error mean 
shRNA  short-hairpin RNA 
Smac  Second mitochondria derived activator of caspases 
SSC  Sideward scatter 
TAB1  TAK 1-binding protein 1 
TAK1 TGF-β-activated kinase 1 
TBS-T  Tris buffered saline with tween 
TEMED  N, N, N’ N' tetramethylethylene diamine 
TG Transglutaminase 
TNF  Tumor necrosis factor 
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TNF-R1  TNF receptor 1 
TRAIL  TNF-related apoptosis inducing ligand 
UBC  ubiquitin-conjugation 
VDAC  Voltage dependent anion channel 
WB  Western blot 
XAF1 XIAP associated factor 1 
XIAP  X-chromosome linked IAP 
zVADfmk  N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone 
∆Ψm Mitochondrial transmembrane potential 
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2 Alphabetical list of companies 
 
Abbott Laboratories Abbott Park, Illinois, USA 
Agfa  Cologne, Germany 
Alexis  Grünberg, Germany 
Amaxa  Cologne, Germany 
Ambion  Hamburg, Germany 
Amersham Bioscience Freiburg, Germany 
Amersham Pharmacia Biotech  Uppsala, Sweden 
Applichem  Darmstadt, Germany 
Applied Biosystems  Foster City, CA, USA 
Assinex Ltd. Moscow, Russland 
Axxora Deutschland GmbH Lörrach, Germany 
Bachem  Bubendorf, Germany 
BD Biosciences  Heidelberg, Germany 
BD PharMingen  Heidelberg, Germany 
Beckman Coulter  Krefeld, Germany 
Becton Dickinson  Heidelberg, Germany 
Berthols detection Systems  Pforzheim, Germany 
Biochrom AG  Berlin, Germany 
Biomol  Hamburg, Germany 
BioRad  Munich, Germany 
Biotrend Chemikalien GmbH Cologne, Germany 
Biozol  Eching, Germany 
Calbiochem  Schwalbach, Germany 
Canon  Krefeld, Germany 
Cayman Chemical  Ann Arbor, USA 
Cell Signaling  Frankfurt, Germany 
Clontech  Mountain View, USA 
Dharmacon  Lafayette, CO, USA 
Dianova  Hamburg, Germany 
Fuji  Düsseldorf, Germany 
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Gerhard  Königswinter, Germany 
Gibco/Invitrogen  Karlsruhe, Germany 
Immunotech  Marseille, France 
Invitrogen  Karlsruhe, Germany 
Kodak  Rochester, USA 
Li-COR Biosciences GmbH Bad Homburg, Germany 
MBI-Fermentas  St. Leon-Rot, Germany 
Merck Biosciences  Darmstadt, Germany 
Millipore  Schwalbach, Germany 
Molecular Probes/Invitrogen  Karlsruhe, Germany 
Novagen  Darmstad, Germany 
Olympus Optical  Hamburg, Germany 
PAA Laboratories  Cölbe, Germany 
PAN Biotech  Aidenbach, Germany 
Peqlab Biotechnologie GmbH  Erlangen, Germany 
Perkin Elmer  Überlingen, Germany 
Peske  Aindling-Arnhofen, Germany 
Promega  Mannheim, Germany 
Promocell  Heidelberg, Germany 
R&D Systems  Minneapolis, USA 
Roche  Mannheim, Germany 
Roth GmbH  Karlsruhe, Germany 
Santa Cruz  Heidelberg, Germany 
SERVA Electrophoresis GmbH  Heidelberg, Germany 
Sigma-Aldrich  Taufkirchen, Germany 
StemCell Technologien Inc.  Vancouver, Canada 
Stratagene  La Jolla, USA 
Tecan  Crailsheim, Germany 
TILL Photonics  Gräfelfing, Germany 
TPP  Trasadingen, Switzerland 
Upstate  Lake Placid, NY, USA 
Zeiss  Oberkochen, Germany 
 
VII Appendix 
99 
 
3 Publications 
ORIGINAL PUBLICATIONS: 
L Schyschka, A Rudy, I Jeremias, N Barth, GR Pettit and AM Vollmar. Spongistatin 1: a 
new chemosensitizing marine compound that degrades XIAP. Leukemia 2008 Sep; 
22(9):1737-45 
L Schyschka, A Rudy, J Rollinger, H Stuppner, KT Wanner, M Gräber, T Berg, A Frieberg, 
M Sattler, AM Vollmar. T8, new chemosensitizing agent for the cancer treatment. In 
preparation. 
POSTERS: 
Schyschka, L., Barth, N., Bliem, C., Stuppner, H., Vollmar, A.M.(2006): Search by virtual 
screening techniques for XIAP inhibitors which target BIR3 domain. Poster presentation 
(01.10.2006) at the 14th Euroconference on Apoptosis in Chia, Sardinia, Italy. 
Schyschka, L., Rudy, A., Stuppner, H., Vollmar, A.M. (2007): Characterization of novel non-
peptidic inhibitors of the anti apoptotic target Bir3. Poster presentation (11.10.2007), 
Jahrestagung der DPHG in Erlangen, Deutschland.  
Schyschka, L., Pfisterer, P.H., Stuppner, H., Vollmar, A.M. (2007): Characterization of novel 
inhibitors of the apoptosis regulating target XIAP-BIR3. Poster presentation (07.12.2007) at 
the 1st Life-Science PhD Symposium in Munich, Germany. 
U. M. Schneiders, L. Schyschka, N. Barth, A. M. Vollmar. Characterisation of apoptosis 
signal transduction induced by spongistatin 1 in MCF-7 cells. 48th Spring Meeting of the 
Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, 
March 13-15, 2006, Mainz, Germany. Naunyn-Schmiedeberg’s Archieve of Pharmacology, 
Vol. 375 
Bliem, C.B., Schyschka, L., Rollinger, J.M., Langer, T., Vollmar, A.M., Stuppner, H. (2006): 
Pharmacophore modelling on the apoptosis regulating target XIAP-Bir3. Poster presentation 
at the 54th Annual Congress on Medicinal Plant Research, August 29th to September 2nd 2006 
in Helsinki, Finland. Abstract: Bliem, C.B. et al. (2006) Planta Med 72, P084, 1008. 
Pfisterer, P.H., Rollinger, J.M., Schyschka, L., Vollmar, A.M., Stuppner, H. (2008): In silico 
discovery of natural chemosensitizers from Eriobotrya japonica. Poster presentation 
(05.08.2008) at the 7th Joint Meeting of AFERP, ASP, GA, PSE & SIF, August 3rd to 8th 2008 
in Athens, Greece. Abstract: Pfisterer, P.H., et al. (2008) Planta Med 74, PG23: 1153. 
 
LECTURES: 
Barth, N., Schyschka, L., Rudy, A., López-Antón N., Pettit, G. R. and Vollmar A. M. 
Spongistatin-1 induces protein degradation of inhibitor of apoptosis and mitochondrial cell 
death in a CD95/FAS receptor and caspase-8-independent manner in human leukemia Jurkat 
T cells. 47th Spring Meeting of the Deutsche Gesellschaft für experimentelle und klinische 
Pharmakologie und Toxikologie, April 4-6, 2006, Mainz, Germany. Naunyn-Schmiedeberg’s 
Archieve of Pharmacology, Vol. 372 
VII Appendix 
100 
 
Barth, N., Schyschka, L., Bliem, C., Stuppner, H., and Vollmar A. M. Identification of novel 
XIAP inhibitors targeting BIR3 by a pharmacophore-based virtual screening. 48th Spring 
Meeting of the Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und 
Toxikologie, March 13-15, 2007, Mainz, Germany. Naunyn-Schmiedeberg’s Archieve of 
Pharmacology, Vol. 375  
Rudy, A., Schyschka, L., Pfisterer, P., Stuppner, H., and Vollmar AM. T8- a novel inhibitor 
of the anti-apoptotic protein XIAP. BIOVARIA, Munich, May 08, 2008. 
Presenter underlined 
VII Appendix 
101 
 
4 Curriculum vitae 
 
Personal Data  
Name  Lilianna Schyschka 
Date of Birth  September 26th, 1978 
Place of Birth  Pyskowice, Poland 
Nationality Polish, German 
 
 
Academic Education  
01/2005 - 02/2009 
Ph.D. Thesis at the Department of 
Pharmaceutical Biology, LMU Munich, Chair 
Prof. Dr. A. M. Vollmar 
10/1997 - 02/2002  Study of biology at the Silesia University, 
Diploma 
 
 
School Education  
9/1993 - 5/1997 Lyzeum, Pyskowice, Poland; Abitur 
9/1985 - 5/1993 Primary school, Pyskowice, Poland 
 
 
Work Experience  
09/2003 - 12/2004 
Technician at the Department of 
Pharmaceutical Biology, LMU Munich, Chair 
Prof. Dr. A. M. Vollmar 
8/2001 – 3/2002 
Teacher at the primary school, Katowice, 
Poland 
 
VII Appendix 
102 
 
5 Acknowledgments 
 
First and foremost, I would like to thank Prof. Dr. Angelika M. Vollmar for persuading me to 
make the Ph.D. study in her laboratory. I am grateful for her support and optimism. Her 
sentence, “now it is making the whole project much more interesting Mrs. Schyschka”, was 
for me a driving force during the whole time of this work. 
Sincere thanks are given to all members of my thesis committee for their time and efforts, 
especially to Prof. Dr. Frank Böckler for acting as second examiner. 
Special thanks go to my fellow workers: Anders Frieberg from Prof. Michael Sattler lab and 
Martin Gräber and Thorsten Berg from MPI, Martinsried. I have had a great luck to meet you. 
I am very thankful group of Prof. Dr. H. Stuppner for virtual screening experiments and group of 
Prof. Dr. K. T. Wanner for T8 synthesizing. Lots of thanks go to Dr. I. Jeremias for patient 
probes analyses and the great support with the interpretation of the results and discussion. 
Lots of thanks go to the current and former members of my lab for friendly and motivating 
work atmosphere. Especially I would like to thank Anita for her presence during my whole 
study as a colleague, supervisor and just friend giving me a great support. I would like to 
thank also Hanna for her help. 
Lots of thanks go to my technical colleagues: Jana, Rita, Mrs. Schnegg, Bianca and 
Bernadette for their support in experimental work. I have never forgotten where I came from. 
Last but not least I would like to thank my family and Krzysiowi for never-ending support 
and for just being there whenever I needed him. 
